Review: Tackling drug resistant infection outbreaks of global pandemic Escherichia coli ST131
using evolutionary and epidemiological genomics
Tim Downing, School of Biotechnology, Faculty of Science and Health, Dublin City University,
Dublin 9, Ireland.
Email: tim.downing@dcu.ie
Abstract: High-throughput molecular screening is required to investigate the origin and
diffusion of antimicrobial resistance in pathogen outbreaks. The most frequent cause of human
infection is Escherichia coli, which is dominated by sequence type 131 (ST131), a set of rapidly
radiating pandemic clones. The highly infectious clades of ST131 originated firstly by a
mutation enhancing virulence and adhesion. Secondly, single-nucleotide polymorphisms
occurred enabling fluoroquinolone-resistance, which is near-fixed in all ST131. Thirdly, broader
resistance through beta-lactamases has been gained and lost frequently, symptomatic of
conflicting environmental selective effects. This flexible approach to gene exchange is worrying
and supports the proposition that ST131 will develop an even wider range of plasmid and
chromosomal elements promoting antimicrobial resistance. To stymie ST131, deep genome
sequencing is required to understand the origin, evolution and spread of antimicrobial resistance
genes. Phylogenetic methods that decipher past events can predict future patterns of virulence
and transmission based on genetic signatures of adaptation and gene exchange. Both the effect of
partial antimicrobial exposure and cell dormancy caused by variation in gene expression may
accelerate the development of resistance. High-throughput sequencing can decode measurable
evolution of cell populations within patients associated with systems-wide changes in gene
expression during treatments. A multi-faceted approach can enhance assessment of antimicrobial
resistance in E. coli ST131 by examining transmission dynamics between hosts to achieve a goal
of pre-empting resistance before it emerges by optimising antimicrobial treatment protocols.
Keywords: population genetics; bacterial infection; recombination; horizontal gene transfer;
epidemic; spread; transmission; antimicrobial resistance; clone; pathogen.
1. The advent of genome-based Escherichia coli monitoring
The rate of infectious disease outbreaks globally increased significantly during 1980-2013 [1,2].
Understanding the transmission dynamics of antimicrobial resistance (AMR) during infections
necessitates deep molecular screening [3,4]. The most informative tools for epidemiological
investigation of AMR exploit emerging high-throughput technologies [5], of which genome
sequencing is becoming standard for resolving the origins of outbreaks over timespans ranging from
centuries to days [6]. Only such tools can trace the transmission of infection outbreaks: other genetic
profiling methods such as multi-locus sequencing typing (MLST) of housekeeping genes or pulse-field
gel electrophoresis (PFGE) are not sufficiently discriminatory [7].
Although PFGE is still used internationally for reconstruction the evolution of bacterial outbreaks, its
reproducibility between labs can be inconsistent [8] due to variability in genome-wide restriction
enzyme site frequency. This can be reduced with use of standardised protocols, materials, and
interpretive criteria. However, its low discriminatory power for ST131 [9] suggests other methods are
superior [10].
MLST has moderate power to determine sequence type (ST) given sufficient elapsed time [11] but is
limited by selecting a small number of genes from the genome [12] (Table 1). The Pasteur MLST
system genes numbers eight genes: DNA polymerase (dinB), isocitrate dehydrogenase (icdA), p1

aminobenzoate synthase (pabB), polymerase PolII (polB), proline permease (putP), tryptophan
synthase subunits A and B (trpA/trpB) and beta-glucuronidase (uidA)
(www.pasteur.fr/recherche/genopole/PF8/mlst/EColi.html). This differs from the Achtman scheme,
which uses seven housekeeping genes: adenylate kinase (adk), fumarate hydratase (fumC), DNA
gyrase subunit B (gyrB), icd, malate dehydrogenase (mdh), adenylosuccinate dehydrogenase (purA),
ATP/GTP binding motif (recA) [13]. Over shorter timescales, MLST is limited [14]: genome
sequencing can be considered simply as an extension of MLST that offers an expanded set of genes
and thus finer resolution, which is critical for fighting rapid clonal expansions.
The comprehensive profiling provided by genome sequencing has enabled the production of new
antimicrobials, diagnostics and surveillance systems, and is a fundamental shift in practice in
infection control that enables more accurate pathogen tracing [15]. An example is the
enteroaggregative ESBL E. coli O104:H4 summer 2011 outbreak that infected thousands and
killed many in France and Germany [16]. Its source was initially misidentified (but later clarified
as fenugreek seeds), and the incubation time in patients was eight days, and progression from
diarrhoea to haemolytic-uremic syndrome a mere five days [17]. This indicates a short timespan
for the medical application of molecular technologies. The draft genome was sequenced within
three days and a consensus genome sequence was reconstructed within two further days [18],
allowing validation of discovered AMR markers within 16 days [19]. In other examples, genome
sequencing successfully determined the number of origins of ST131 CMT-X-15-positive
infections in a neonatal unit [20] and in enterohaemorrhagic O157:H7 isolates [21]. Similar
strategies have worked in clinical settings for other bacterial species like Staphylococcus aureus
and Clostridium difficile [22].
Recent methodological advances have dramatically improved the accuracy and cost efficiency of highthroughput sequencing technologies, primarily in relation to genome sequence contiguity through
better library preparation or genome assembly. At present, genomes can be amplified from just 20+ pg
DNA [23] or even single colonies [24], and up to 384 samples can be sequenced simultaneously [25].
Sequencing single bacterial cells would not require prior cultivation, and therefore could detect cells
on environmental surfaces [26], as well as removing biases associated with growing large numbers of
cells, which favours those best-suited to media or that grow faster. Sequence depth and repetitive
sequence biases can be reduced by using microwell displacement amplification systems. These have
produced assemblies of over 90% of an E. coli genome [27]. De novo assembly of E. coli and other
bacterial genomes as a single unit using long sequence reads is now viable using single-molecule realtime sequencing [28,29]. This approach can differentiate carbapenemase-producing elements in E. coli
[30], determine the precise origins of the linked mobile genetic elements (MGEs) like insertion
sequences (ISs) [31], and also create gapless enterohaemorrhagic O157:H7 EDL933 genome with no
ambiguous SNPs [32]. Additionally, other strategies like nanopore sequencing have produced highresolution E. coli genomes [33].
2. Escherichia coli ST131 is a major global health issue
E. coli is the most frequent cause of acute bacterial infections [4], particularly blood stream infections
(BSIs) and urinary tract infections (UTIs) [34]. E. coli causing UTIs and BSIs are not genetically
distinct and can transfer between distinct environments [35]. Uropathogenic E. coli cause 80% of UTIs
[36] and infect 20% of adult women at least once in their lifetime [37]. Approximately 50% of
hospital-acquired (HA) and 70-95% of community-acquired (CA) UTIs are caused by E. coli, and
these are suspected to originate from intestinal colonisers [37,38]. There are multiple potential sources
of E. coli UTIs and BSIs because it contaminates food [39,40,41] such as fruit [42] and meat [43], and
infects companion animals [44] like cats [45] and dogs [46].
2

E. coli are the most frequent extended spectrum beta-lactamase (ESBL)-producing bacterial species
and are common globally: ESBL-producers account for 19-61% of E. coli in Spain [47], 41% in Israel
[48], 41% in Japan [49], 47% [50] to 56% [51] in the USA, 78% in Canada [52] and 91% in Ireland
[53]. The most significant threat among ESBL E. coli is sequence type O25b:H4-B2-ST131, a set of
pandemic clones from phylogroup B2 that is dominant worldwide [54,55,56]. B2 is associated with
extraintestinal infection, but is also present asymptomatically in humans [57,58]. There is evidence
that B2 diverged early among E. coli groups and is composed of nine subclasses [59], of which ST131
is a basal group [60]. O25b ST131 has been detected in many countries, and serotypes O16:H5, O(not
typeable):H4, and O157 have also been observed in Australia [61], China [62], Denmark [63], Japan
[64], Spain [47], the USA [65] and the UK [54,66].
Even though it was first reported in 2002 [67], ST131 is not new. Global ST131 isolates taken from
humans, animals and environmental locations evaluated using PFGE include samples from 1967, 1982,
1983, 1985, 1986, and 22 from 1990-99 [50]. The earliest other ST131 are from Sweden and Britain
and date to 1968, with others from the 1970s (7), 1980s (9) and 1990s (16) [68] – as well as one from
1985 [65].
Bacterial AMR is a major threat to public health [69]: AMR in E. coli is evident worldwide [4] and
encompasses many compounds [24,70]. AMR in E. coli is becoming more frequent [71] and is driven
by environmental exposure [72], such as in effluent waste water [73,74] and soil treated with manure
from antibiotic-treated livestock [75]. In the UK from 1991-2012, antibiotic treatment failure jumped
by ~12% and was more frequent in certain second-line antimicrobials (such as quinolones and
cephalosporins) than in first-line ones (penicillins, macrolides, flucloxacillins) [76]. 75% of E. coli
from 1997-2007 in Irish hospitals displayed AMR to eight or more of 16 antimicrobials [77]. ESBLproducing E. coli are resistant to cephalosporins and fluoroquinolones, leaving carbapenems as the sole
last-resort antimicrobial [4]. However, multi-AMR ESBL E. coli with carbapenem-resistance are now
detected with alarming frequency [78] and in Algeria [79], China [80] and Ireland [81] for ST131.
ST131 represents a universal problem whose evolutionary epidemiology needs deeper study. Little is
known about how it evolves and spreads on a local scale [82] despite a high infection rate in neonatal
[20,83,84,85] and childcare facilities [86]. As a fraction of total E. coli infections, ST131 infection
rates are proportionally higher in long-term care facilities (LTCFs) (76%) than hospitals (49%) and the
public (15%) [87]. This may be driven by the acquisition of CTX-M (cefotaximase) elements, which
are beta-lactamases (bla) that hydrolyse beta-lactam rings [88]: UTIs caused by blaCTX-M-positive
ST131 are now common in LTCFs [89], hospitals [90] and the community [91]. Current hypotheses on
the sources of E. coli have identified LTCFs as a closed microenvironment in which AMR bacteria
evolve [92], and subsequently they diffuse into the wider community, spreading AMR alleles [93].
3. The genomic landscape of antimicrobial resistance in E. coli
Commonly E. coli genomes are separated into the largely chromosomal highly-conserved core genome
and the accessory genomes. Notably, the core genome varies between studies [94] because it is
composed of genes present in all samples for that analysis [95]. The accessory genome typically has
much lower sequence conservation and encodes non-essential traits associated with virulence and
antimicrobial metabolism [96]. It represents a major component of microbial variation and includes
MGEs like plasmids, transposable elements (TEs), pathogenicity islands, and prophages.
E. coli undergo extensive horizontal gene transfer (HGT) [97]: HGT accounts for ~31% of genomewide variation in ST131 [98]. Genes arising by HGT are frequently associated with duplications,
which can permit new functions among the two gene copies [99]. HGT typically occurs through three
processes: the primary one is transduction via bacteriophages after cell lysis and invasion via
3

homologous recombination. ST131 acquire AMR through extrachromosomal MGEs from
bacteriophages [100], or the integration of prophage DNA into chromosomes [101]. Prophage
elements account for over 35% of E. coli CDS variation [102], and encode genes linked to virulence
[103], growth during nutrient deficit [104], transcriptional regulation [105], AMR [106] and biofilms
[107]. During generalised transduction, HGT segment length is a function of phage type. Other options
for HGT are the transformation of local DNA from dead cells, or conjugation mediated by plasmids,
TEs, integrons or integrating conjugative elements (ICEs). Homologous recombination between ICEs
increase their diversity [108]. TEs such as ISs have a high frequency of integration and excision, and
mediate both AMR gene composition and their expression rates. Although HGT is generally a function
of sequence homology, but TEs do not need high levels to insert.
More detailed knowledge of AMR gene types and expression rates can help optimise antimicrobial
treatments [109,110]. A large number of ST131 genomes have been published. The first was NA114
from an Indian UTI: a 4,936 Kb genome with a GC content of 51.2% and of which 88.4% was coding
sequence (CDS) [111]. In comparison, genome JJ1886 from a UTI was 5,130 Kb and genetically more
representative of the super-spreading subgroups within ST131 [112]. Notably, JJ1886 contained a
chromosomal CTX-M-15 element due to a partial insertion of a Tn3 element into a lambda-like
prophage locus. Isolate EC958 from the UK was also blaCTX-M-15-positive and provided a 50.7%
GC 5,110 Kb genome somewhat distinct from NA114 and JJ1886 [113], perhaps due to its earlier
isolation date. It is important to note that the number of genes, tRNAs and rRNAs in NA114 (4,875; 67;
3), JJ1886 (5,086; 88; 22) and EC958 (4,982; 89; 7) may differ due to differences in sequence library
preparation and genome assembly: comparisons must be cognisant that not all genomes are created
equal.
4. Antimicrobial resistance genetically defines ST131
The most closely related clonal complexes (ST1876 and ST95) provide a genetic definition for ST131
(Figure 1). ST131 possesses a variety of genes associated with virulence [47,114] and pathogenesis
[115] (Table 1). A key one is the fimH gene encoding a type 1 fimbrial adhesion protein expressed on
the cell membrane. ST131 encompasses firstly serotype O16:H5 with a fimH41 allele: this is
equivalent to Clade A from Petty et al [116]. ST131 secondly includes serotypes O25b:H4, some of
which possess fimH22 allele, corresponding to Clade B [116]. Genomes from 1967, 1983 (avian
infection), 1985, 1990 (avian), 1992, 1995 (chicken) and 1997 were all fluoroquinolone-sensitive
fimH22 (Clade B) ST131 [98]. Genome sequencing and the Pasteur MLST system can distinguish
O16:H5 from O25b:H4, but not the Achtman MLST scheme.
The remaining ST131 belong to a group named H30 (or Clade C [116]) defined by their acquisition of
a fimH30 allele: the earliest date of appearance of H30 is at least 1997 [50]. A minority of H30 appear
to have lost fimH30 for fimH22/35 or rarer fimH variants [118]. Fluoroquinolone-sensitive ST131 was
common prior to 2000, but is now rare. This is due mutations in two genes encoding DNA gyrase
subunit A (gyrA) and DNA topoisomerase 4 subunit A (parC). Nested within H30 is H30-R, which
accounts for 58% of ST131 and is becoming more prevalent [116]. H30-R is nearly always
fluoroquinolone-resistant – but this can be lost [118].
A subgroup of H30-R named H30-Rx is a recent radiation dating to at least 2002 and is nearly always
blaCTX-M-positive [98,116]. Just three genome-wide SNPs distinguish H30-Rx from other H30-R. It
is the main driver of increasing rates of fluoroquinolone-resistance [120]. BlaCTX-M-15 is the most
frequent H30-Rx CTX-M element type and originated from Kluyvera in the early 2000s [119], such
that 49% of E. coli LTCF samples from 2004-2006 were blaCTX-M-15-positive ST131 [121]. Other
older fluoroquinolone-resistant blaCTX-M-15-positive H30-Rx with published genomes predating
2006 are EC958 (March 2005) [113], several from 2000-05 isolated in Canada [116], and from 2002
4

again in Canada, but also 2003 in Korea and 2005 in Portugal [98]. Such isolates could be essential for
determining the origins of H30-Rx. BlaCTX-M-15 is also found less commonly in ST38, ST405 and
ST648 [120].
FIGURE 1. ST131 GENETIC GROUPS AND ACQUISITION OF DRUG-RESISTANCE CHANGES.

THIS CLADOGRAM SHOWS ST1876 AND ST95 AS THE MOST CLOSELY RELATED CLONAL COMPLEXES TO
ST131 (WITH PUBLISHED GENOMES). H41 IS IN SEROTYPE O16:H5 AND IS KNOWN AS CLADE A (H41)
[116]. H22 IS A SET OF O25B:H4 ST131 CALLED CLADE B [116]. H30 IS A SUBGROUP OF O25B:H4
ST131 DEFINED BY THEIR ACQUISITION OF THE FIMH30 ALLELE (DARK GREEN) [98]: THIS IS CALLED
CLADE C. H30-R IS A SUBSET OF H30 THAT ARE NEARLY ALWAYS FLUOROQUINOLONE-RESISTANT
(EMERALD GREEN), LARGELY DUE TO ALLELES 1AB IN GYRA AND 1AAB IN PARC. WITHIN THIS GROUP,
H30-RX HAVE BLACTX-M-15 (BRIGHT GREEN) [98] BUT NOT ALWAYS [116]. THIS DIAGRAM DOES NOT
MEAN THAT H30, H30-R OR H30-RX ARE MONOPHYLETIC [68].
5. The key antimicrobial resistance elements in ST131
Numerous core genome mutations are implicated in ST131’s AMR [122]. These include regulators of
drug efflux, repressor of the marRAB (multiple antibiotic resistance) operon (marR), and repressor of
acrAB (achromobactin outer membrane receptor) genes (acrR), that respond to drugs associated with
high fitness costs. Others are L42R in ribosomal gene S12 (rpsL105); a transposon mediating
resistance to tetracycline (Tn10); S80I and E84V in parC to fluoroquinolones; ciprofloxacin and
nalidixate thanks to changes at gyrA (most frequently S83L and D87N) [123]. Chromosomal ampClike cephalosporinases are also common in E. coli [48].
ST131’s virulence genes are used to categorise it into distinct virotypes [68]. The aerobactin receptor
(iutA), group 2/3 capsule synthesis (kpsM II/III) and fimH genes are part of a system for defining
extraintestinal E. coli [124,125]. These are markers for H30-Rx, along with Afa adhesion (afa), Drbinding adhesion (dra), virotype A and capsule (K100) genes [68]. ST131 virulence factor genes are
typically located in pathogenic islands or MGEs and encode toxins, adhesions, lipopolysaccharides,
polysaccharide capsules, proteases, and invasins (Table 1). Other genes universal in ST131 include
secreted autotransporter toxin (sat), yersiniabactin receptor (fyuA), uropathogen-specific protein (usp),
5

pathogenicity island marker (malX), adhesion receptor (iha), outer membrane receptor (ompT),
aerobactin (iucD) and serum resistance associated (traT) [126].
ST131 has different plasmids from multiple incompatibility groups (Inc) such as IncF, IncI1, IncN and
IncA/C. IncF are limited to Enterobacteriaceae, are the most frequent plasmids in ST131 [127], and
have a major role in determining AMR. Typically they are >100kb long and maintained at a low
number of copies. Three types of IncF plasmids have been found in ST131, not including complex
fusions: IncFIA, IncFII and IncI1 [127]. These plasmids typically possess multiple AMR, betalactamase, virulence, toxin and antitoxin elements. Conjugation of IncFII plasmids have facilitated the
pervasive spread of blaCTX-M elements, especially blaCTX-M-15. A majority of isolated ST131 have
IncFII pEK516 plasmids, which has 103 genes including blaCTX-M-15, blaOXA-1, blaTEM-1,
chloramphenicol acetyltransferase (catB4), tetracycline efflux pump (tetA) and plasmid stability (stbB)
for stable plasmid inheritance [128]. In the latter study, plasmid pEK516 also contained
aminoglycoside acetyltransferases allowing resistance to aminoglycosides, ciprofloxacin (both via
aac(6’)-Ib-cr) and gentamicin (via aac(3)-II).
Plasmids contain genes encoding various beta-lactamases that are grouped into Ambler classes A
(blaCTX-M, blaTEM, blaKPC, blaSHV); B (blaVIM, blaNDM, blaIMP); C (blaCMY, ampC-related
like blaDHA); D (blaOXA). Classes A/C/D use serine for beta-lactam hydrolysis, whereas B are
metallo-beta-lactamases that use divalent zinc ions [129]. Beyond blaCTX-M in class A, TEM betalactamases are the most frequent ESBL in E. coli more broadly. They are exchanged extensively
between species: for example, TEM-52C in E. coli is mediated by an IncI1-g plasmid on a Tn3
transposon [130] and has been found in Salmonella [131]. SHV beta-lactamases are less common in E.
coli, but are abundant in K. pneumoniae, from which ST131 has acquired other beta-lactamases [132].
Class A KPC-2 (K. pneumoniae carbapenemase) is the most common carbapenemase type [120]. This
can impair cephalosporins, monobactams and penicillins, as well as carbapenems, and has spread to
China [80], France [133], Ireland [78,81] and the USA [134]. Other carbapenemases include class B
metallo-beta-lactamases like Verona integron-encoded metallo-beta-lactamase (VIM), which has been
found in Italy [135], and blaIMP-8, which has been detected in Taiwan [136].
Class B NDM-1 (New Delhi metallo-beta-lactamase)-positive ST131 has been found in India [137]
where it may have originated in E. coli by in vivo conjugation with K. pneumoniae in 2009 or earlier
[132]. BlaNDM-1-positive ST131 is now common in northern India (6% in Varanasi [138]), southern
India (7% in Mumbai [139]) and northern Pakistan (15% [140]). BlaNDM-1 has been found on fastspreading IncFII plasmids as well, along with Class D carbapenemase blaOXA-1 (oxacillinases)
together with aminoglycoside resistance genes [141]. The rapid spread of blaNDM-1 in many species
provides an example of how easily certain AMR genes can be spread.
Lastly, class C includes plasmid-mediated ampC beta-lactamases blaDHA-1 [49], which was first
found in Salmonella enterica [142], and blaCMY-4 (active on cephaycins) [48] and blaCMY-2
[49,143] – the latter is a cephamycinase originally transferred from Citrobacter species. Some ampC
genes are chromosomal, but possess a much lower expression rate than the more common plasmidmediated ampC genes [48].
6. How did ST131 adapt to be so successful?
Bacterial infectious disease is driven in part by rapid mutation rates (~10-5 per genome per generation
in E. coli) [144], short generation times [145], and non-lethal antimicrobial doses due to non-adherence
[146]. Remarkably, AMR may have no fitness cost and may even increase fitness in E. coli [147,148].
ST131 is highly resistant without any fitness cost [127], even more so in CA compared to HA ST131
6

isolates [149]. As outlined, the three key changes define H30-Rx ST131: the acquisition of fimH30,
fluoroquinolone-resistance switches and beta-lactamase gains. In contrast to the single acquisitions of
fimH30 and fluoroquinolone-resistance, the type of beta-lactamase varies, and they are lost and
recovered frequently. Consequently, antimicrobial treatments have inadvertently created the H30-Rx
superbug, and associated fitness costs may be linked with beta-lactamases, but less so for fimH30, 1AB
in gyrA and 1aAB in parC. As acknowledged above, there are rare cases of fimH30 loss and gyrA/parC
mutation within H30-Rx.
(i) Extensive horizontal gene transfer
ST131 is common in UTIs and BSIs, but not at other anatomical locations [150]. In spite of pervasive
HGT, DNA exchange with other bacterial species is rare, affecting just ~0.4% of the core genome
conserved across the E. coli genus [151]. UTI-causing ESBL-positive ST131 acquire resistance
through HGT with other ST131 colonising the same individual, but rarely from other E. coli
phylogroups [54]. Indeed, ST131 is frequent in poultry [152] but retains a distinct set of blaCTX-M
and blaTEM-52 elements despite high overall genetic similarity [153]. Naively, this suggests previous
HGT with Kluyvera [119] and K. pneumoniae [132] is rare. However, recent examples of K.
pneumonia derived plasmids contributing blaCTX-M-27 genes to ST131 [154] is consistent with a
proposal of alarming potential genetic flexibility in ST131.
(ii) Maintenance of a broad resistome
ST131 regulates the activity of its resistome: its entire complement of AMR genes. There is evidence
of functional robustness and redundancy in the resistance mechanisms of E. coli’s “proto-resistome”
comprising penicillin-binding proteins, cell wall modifying enzymes and cell division genes [155]. A
sequencing approach could assess this in a comprehensive manner. Expression of 61 genes is
associated with small increases in tolerance to 86 antimicrobial-related compounds [156]. Many
potential AMR genes remain unknown in E. coli [157], even though their activities vary even within
putatively clonal cell populations [158] and the mechanism of action of many antimicrobials remains
unclear [159].
(iii) Regulatory fine-tuning of gene expression
Regulatory sequences alter AMR through gene expression levels [160] including bursting [161] and
transitions between pathogenic and non-pathogenic states [126]. Promoters evolved to alter gene
expression rates in response to rapidly changing environmental conditions [162], which can affect
AMR phenotypes by up to 106-fold [163]. Promoter gene expression regulation is higher at nonessential genes with lower sequence conservation, and their activity rates are more variable than those
of essential genes [164]. During multi-drug exposure, 30% of E. coli expression variation is attributed
to promoter mutations [165] – for example, a mutation T32A at a beta-lactamase ampC gene promoter
elevates expression rates genome-wide [166].
(iv) Cross-antimicrobial resistance and compensatory mutations
Synergy and antagonism between different antimicrobials is pervasive [167], even to the point that
simultaneous synergy and antagonism is possible (a Harvey Effect). Some compensatory mutations are
specific to individual antimicrobials but others promote cross-AMR simultaneously [168]. Feedbackbased cross-AMR in response to combination treatments is a function of the number of unlinked
(positive) gene regulatory networks [169]. AMR is reduced by negative epistasis during cyclical
treatment, which decreases resistance to both drugs more effectively than to single drugs – nearly as
well as dual drug therapies [170]. Certain compensatory mutations alter AMR without being clearly
associated with the phenotype – for instance, blaCTX-M-linked carbapenem-resistance requires water
channel (porin) gene loss to mitigate fitness costs [171]. Additionally, structural rearrangements at ISs
are associated with rapid increases in fitness during long-term E. coli evolution [172].
7

(v) Resistance through cell growth arrest
Antimicrobials limit E. coli growth [173], which is controlled by gene expression [174]. Growth
depends on environmental conditions and is controlled by the concentration of transcription-associated
proteins [175]. Even without a specific stress, cells spontaneously enter and exit a quiescent nongrowth state during both log and stationary growth phases [176]. Lowered expression is more strongly
associated with non-essential genes like toxins [164]. There are 22 toxin-antitoxin systems in E. coli
K12 that can be recruited during environmental stress to regulate growth, affecting biofilm formation
[177]. For example, in the hipBA toxin-antitoxin system, antitoxin HipB represses serine-threonineprotein kinase HipA but has a short half-life. When HipB levels fall, HipA phosphorylates a glutamyl
tRNA synthetase to mimick starvation [178], reducing translation and slowing growth, resulting in a
non-growing phenotype [179].
7. Stopping ST131:
(i) Evolutionary phylogenomics and fitness measurement
Pathogens resist antimicrobials by evolving: consequently, analysis of evolution is needed [180] which
should operate on a genome-wide basis for outbreaks like ST131 to more finely resolve of
evolutionary patterns at all potential AMR factors [181]. Genome-based evolutionary analysis and
real-time diagnostic evaluation is now as cheap and time-effective as conventional approaches [182]
and informative bioinformatics strategies now underpin improvements in clinical microbiology [183].
Variation arising by recombination between strains can be deduced from the genome-wide DNA
mutation density distribution [181]: signatures of HGT have much higher polymorphism rates,
reflecting the mutational time spent in a different species [184]. For H30-Rx, this includes MGEs,
integrated phage DNA and capsule-related genes [185]. Comparing the most likely genealogy at a
given panel of SNPs (haplotype) to the mean signal across the genome can identify ancestral and
recent recombination between and within subpopulations [186] and determine the phylogeographic
origin of specific recombination events in a coalescent framework [187]. Phylogenetic and
genealogical histories at regions arising through HGT deviate substantially from the mean genomewide phylogenetic signal [188,189].
New beneficial variants increase in frequency faster than average [190] and retain a more recent time
of origin [191]. Phylogenetic branching topology can measure relative fitness assuming a persistent
source of antimicrobial pressure causing mutations with small fitness effects [192]. The latter is valid
for E. coli because many genes regulate AMR and virulence [156,193]. No variation in relative fitness
would mean low variability in the rates of coalescence of descendent nodes compared with ancestral
ones. In contrast, a high difference in relative fitness would mean highly fit ancestors will produce
many more descendent nodes. This would appear as a radiating population: such as H30 within ST131,
H30-R within H30, H30-Rx with H30-R; what will follow H30-Rx?
(ii) Modelling historical and future epidemiology
Systematic monitoring of infection and transmission in human populations can be used to infer sources
of ST131, including from potential reservoirs like livestock and intestinal colonisers [61]. Current
hypotheses pinpoint the Indian subcontinent as a possible original reservoir for ST131. During the
discovery of ST131 in 2008, there was a high rate of recent travel to this region in those with H30-Rx
ST131 infection in New Zealand [194] and Canada [195,196]. Whether this was caused by both a
single H30-Rx clone and through plasmid-mediated HGT is unclear [197] due to the limited sampling
of the Indian subcontinent prior to 2002. With extensive geographic sampling including samples
particular during the acquisition of fimH30 in the 1990s and fluoroquinolone-resistance sometime
before 2002, phylogenomic reconstruction would address this puzzle.
8

Genome sequencing can help address the rise of AMR [38] by predicting future resistance. The most
likely future dominant subtype of a pathogen is typically the most fit one [198]: this can be applied to
ST131 based on de novo and known mutations at key AMR determinants using frameworks developed
for viruses [199]. The relative rate of allele frequency change reflects its association with antimicrobial
selection pressure [200], and can be measured from time-series genome data [201] to distinguish this
effect from drift [202]. Such sampling over extended periods allows the identification of genes
implicated in adaptation based on the mutation’s age, functional effects, and ancestral phylogenetic
position [203].
Phylodynamic models determine future evolutionary and epidemiological patterns based on
phylogenetic tree structure [204]. Such schemes have revealed missed events during transmission of
tuberculosis [205], pin-pointed an asymptomatic spreader of methicillin-resistant S. aureus between
babies [206], assessed the potential for multiple simultaneous outbreaks to originate from the same
common ancestor [207], and examined evidence for multiple origins of infection [208]. Although such
methods have not yet been applied to E. coli, they can enhance our understanding of the inter-host
spread of AMR.
(iii) Assessing cell growth arrest
Stochastic phenotype switching is common to all domains of life, is accentuated by antimicrobial stress,
and in bacteria is observed as changes in gene expression. This growth-dormancy bistability is an
evolutionary bet-hedging strategy that results in a mix of cells with varying gene expression rates [209].
It arises due to gene regulatory network structure, leading to rare but occasional switches from the
growing wild-type (WT) state to a non-growing dormant one. Cell-cell interactions may affect
variation in gene expression rates [210], allowing this randomness to adaptively drive regulatory
changes.
Cell dormancy causes large shifts in metabolic gene expression [211,212]. This contrasts with
ribosomal gene expression that has buffering mechanisms [174,213] and so scales linearly with cell
growth [214]. E. coli alter their carbon metabolism rapidly [215] by co-regulating enzymes to cope
with rapidly changing environmental conditions [216]. However, metabolic flux is regulated
extensively [217,218] so differing concentrations can produce the same net metabolic effects [219,220]
or affect other pathway components [221]. E. coli optimise gene expression by moderating ribosome
production [222]: this means shifts in metabolic gene expression can be compared to those for
ribosomal RNA, which should match the antimicrobial toxicity and bacterial AMR level. AMR-driven
changes in gene expression vary non-monotonically with dose and are a function of the complexity of
the mechanism: antimicrobials inactivating targets may elicit higher target expression, whereas drugs
causing gain-of-function changes may cause mutation [110]. This means the relative rates of metabolic
and ribosomal gene activity provide sufficient information to deduce AMR levels and types.
(iv) Avoiding partial treatments and cell population heterogeneity
Suboptimal treatment regimens [34], poor compliance [223] and drug pharmacokinetics [224] lead to
spatial structure in antimicrobial concentrations. This is frequent in human and animals both at an
individual level [225] and in groups of treated and untreated patients [226]. At low antimicrobial doses
(such as a minimal selective concentration [227]), WT and resistant cells grow equally well, whereas
only resistant cells would survive when exposed to dose greater than the minimal inhibitory
concentration (MIC). Partial treatment regimens accelerate AMR for mechanisms requiring numerous
mutational steps with small fitness costs by offering a sub-MIC sanctuary where resistant cells can
evolve further despite transiently lowered fitness [226]. However, partial regimens can slow AMR if it
requires few mutational steps or substantial temporary falls in fitness [229]. In addition, the mutational
time required for resistance emergence may be a function of cell density [230].
9

Spatial or temporal variation in treatment application allows WT cells more time to accrue new
mutations, causing faster AMR evolution [228]. These genetically resistant cells are known as type 1
persisters to differentiate them from type 2 persisters that are resistant due to gene expression control
causing non-growth [231]. Although E. coli type 2 persister gene activity depends on adjacent cells
[165], they revert to growth after dormancy ends, and attain exponential growth rates once resistant
mutations occur when all WT cells have died [232]. These type 2 persisters may require a genetic
predisposition [231] and initially comprise just 0.001% of cells [233].
(v) Dissecting measurably evolving infections
A single ST131 infection may become a genetically diverse cell community descended from a recent
common ancestor driven by antimicrobial selective pressure. Multiple populations could exist: for
example S. aureus measurably evolves (30 SNPs and 4 indels in 16 months) to magnify virulence
[234]. Furthermore, distinct Burkholderia dolosa lineages co-exist within individual cystic fibrosis
patients for years and have undergone extensive clonal interference during exposure to antimicrobials
[235]. Soft selective sweeps during host adaptation of Pseudomonas aeruginosa are prevalent,
indicating different loss-of-function mutations may target the same gene within a heterogeneous cell
community [236].
Consequently, deep genome sequencing is required to grapple with mutations in a cell population
[237]. Such population mixes could be described using birth-death [181], logistic growth [238] and
two-level population models within a single infection [239] or a structured environment [240] to
optimise antibiotic treatment protocols [241]. However, there are caveats: high-dose antimicrobial
treatment may give rise to a single dominant variant within the host [110], rare variants may become
more advantageous at differing rates as the host microenvironment changes [190], and mutants may be
pre-existing rather than de novo [123].
Conclusion: Future avenues for ST131 infection genomics
Genome sequencing can predict virulence, toxicity and AMR phenotypes in E. coli ST131 [242]. It is a
pivotal tool for infection control because it facilitates the decoding of molecular mechanisms of
treatment resistance [243] and can dissect clonal outbreaks of monomorphic bacteria [244]. It can
decipher transmission routes and inter-host contact [181], and evaluate genetic diversity within hosts
over time [245]. This evolutionary approach should become the basis for analysing E. coli ST131
outbreaks. A final point is that there are several other possibilities for genome-based AMR control not
discussed here: E. coli post-transcriptional processing disturbs expected correlations between mRNA
and protein levels [246] – this includes AMR-driven regulatory changes by small RNAs [247].
Additionally, epigenetic heterogeneity within E. coli cell populations screened using long-read
sequencing methylation data [248] is associated with extensive regulatory control of phenotypes [249].
Acknowledgments
I thank Cathal Seoighe, Martin Cormican, Dearbhàile Morris and Catherine Ludden (all NUI Galway)
for discussions. This work was supported by the National University of Ireland Galway (Ireland) and
USA National Science Foundation (Grant No. NSF PHY11-25915).
Author Contributions
T.D. conceived and wrote the review.
Conflicts of Interest
The author declares no conflict of interest.
10

Table 1. Genes associated with virulence or ST131 typing. Genes encoding virulence factors (adhesion,
capsules, siderophores, antimicrobial resistance (AMR), toxins) and used to define Extraintestinal E.
coli, H30-Rx ST131 and the Pasteur/Achtman MLST schemes are highlighted.
Gene Name
H7 fliC
iss
malX
ompT
traT
usp
K1/K2/K5
kpsM II
kpsMT III
K100
afa
draBC
fimH
F10 papA
focG
hra
iha
papC/papE/papF/papG
sfa/foc
tsh
iutA
fyuA
ireA
iroN
stbB (pEK516 plasmid)
catB4 (pEK516 plasmid)
tetA (pEK516 plasmid)
aac (pEK516 plasmid)
mphA
acrR
marR
rpsL105
aadA5
sulI
Tn10
dfrA7
gyrA
parC
astA
cnf1
hlyD
pic
sat
vat
dinB
pdbB
polB
putP
trpA/trpB
uidA
icd/icdA
adk
fumC
gyrB
mdh
purA
recA

Gene product
Flagellin variant
Increased serum survival
Pathogenicity island marker
Outer membrane protease T
Serum resistance-associated
Uropathogenic-specific protein
Group 2 capsule variants
kpsM II group 2 capsule
Group 3 capsule
Group 2 capsule variants
Afa adhesin
Dr-binding adhesin
Type 1 fimbriae
P fimbriae subunit variant
F1C fimbriae adhesin
Heat-resistant agglutinin
Adhesion siderophore
P fimbriae operon
F1C fimbriae or S
Temperature sensitive hemagglutinin
Aerobactin receptor
Yersiniabactin receptor
Siderophore receptor
Salmochelin receptor
Plasmid stability
Chloramphenicol acetyltransferase
Tetracycline efflux pump
Aminoglycoside acetyltransferases
Macrolide 2'-phosphotransferase I
Repressor of acrAB genes
Repressor of the marRAB operon
Ribosomal gene S12
Aminoglycoside 3'-adenyltransferase
Dihydropteroate synthase
Transposon - tetracycline resistance
Dihydrofolate reductase type VII
DNA gyrase subunit A
DNA topoisomerase 4 subunit A
Arginine succinyltransferase
Cytotoxic necrotizing factor
Alpha-Hemolysin
Serine protease
Secreted autotransporter toxin
Vacuolating toxin
DNA polymerase
P-aminobenzoate synthase
Polymerase PolII
Proline permease
Tryptophan synthase subunits A, B
Beta-glucuronidase
Isocitrate dehydrogenase
Adenylate kinase
Fumarate hydratase
DNA gyrase subunit B
Malate dehydrogenase
Adenylosuccinate dehydrogenase
ATP/GTP binding motif

Role in virulence
Multiple
Multiple
Multiple
Multiple
Multiple
Multiple
Capsule-related
Capsule-related
Capsule-related
Capsule-related
Adhesion
Adhesion
Adhesion
Adhesion
Adhesion
Adhesion
Adhesion
Adhesion
Adhesion
Adhesion
Siderophore
Siderophore
Siderophore
Siderophore
plasmid stability
AMR
(chloramphenicol)
AMR
(tetracycline)
AMR (multiple)
AMR (macrolide)
AMR (multiple)
AMR (multiple)
AMR (multiple)
AMR (streptomycin)
AMR (sulfonamide)
AMR (tetracycline)
AMR (trimethoprim)
AMR (fluoroquinolone)
AMR (fluoroquinolone)
Toxin
Toxin
Toxin
Toxin
Toxin
Toxin

Typing use

Extraintestinal E. coli definition
Extraintestinal E. coli definition
H30-Rx definition
H30-Rx definition
H30-Rx definition
Extraintestinal E. coli definition

Extraintestinal E. coli definition

Pasteur MLST system
Pasteur MLST system
Pasteur MLST system
Pasteur MLST system
Pasteur MLST system
Pasteur MLST system
Pasteur/Achtman MLST system
Achtman MLST system
Achtman MLST system
Achtman MLST system
Achtman MLST system
Achtman MLST system
Achtman MLST system

11

References
1. Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2013. US Department of Health and Human Services.
2013, www.cdc.gov/drugresistance/threat-report-2013/pdf/ar-threats-2013-508.pdf.
2. Smith, K.F.; Goldberg, M.; Rosenthal, S.; Carlson, L.; Chen, J.; Chen, C.; Ramachandran, S. Global rise in human infectious disease outbreaks. J R Soc
Interface, 2014, 11(101), 20140950.
3. WHO. The evolving threat of antimicrobial resistance - Options for action. 2012, www.who.int.
4. WHO. Antimicrobial resistance: Global report on surveillance 2014. 2014, www.who.int.
5. Reuter, S.; Ellington, M.J.; Cartwright, E.J.; Köser, C.U.; Török, M.E.; Gouliouris, T.; Harris, S.R.; Brown, N.M.; Holden, M.T.; Quail, M.; et al. Rapid
bacterial whole-genome sequencing to enhance diagnostic and public health microbiology. JAMA Intern Med 2013, 173(15), 1397-404.
6. Achtman, M. Insights from genomic comparisons of genetically monomorphic bacterial pathogens. Philos Trans R Soc Lond B Biol Sci 2012,
367(1590), 860-7.
7. Palmer, A.C.; Kishony, R. Understanding, predicting and manipulating the genotypic evolution of antibiotic resistance. Nat Rev Genet 2013, 14(4),
243-8.
8. Noller, A.C.; McEllistrem, M.C.; Pacheco, A.G.; Boxrud, D.J.; Harrison, L.H. Multilocus variable-number tandem repeat analysis distinguishes
outbreak and sporadic Escherichia coli O157:H7 isolates. J Clin Microbiol 2003, 41(12), 5389-97.
9. Johnson, J.R.; Nicolas-Chanoine, M.H.; Debroy, C.; Castanheira, M.; Robicsek, A.; Hansen, G.; Weissman, S.; Urban, C.; Platell, J.; Trott, D.; Zhanel,
G.; Clabots, C.; Johnston, B.D.; Kuskowski, M.A.; MASTER Investigators. Comparison of Escherichia coli ST131 pulsotypes, by
epidemiologic traits, 1967–2009. Emerging Infectious Diseases 2012, 18(4), 598–607.
10. Mathers A.J.; Peirano, G.; Pitout, J.D. Escherichia coli ST131: The Quintessential Example of an International Multiresistant High-Risk Clone. Adv
Appl Microbiol. 2015, 90, 109-54.
11. Sullivan, C.B.; Diggle, M.A.; Clarke, S.C. Multilocus sequence typing: data analysis in clinical microbiology and public health. Molecular
Biotechnology 2005, 29(3), 245–254.
12. Coughlan, S.; Barreira, S.; Seoighe, C.; Downing, T. Chapter 3: Genome-wide variant discovery using sequence assembly, mapping and populationwide analysis. In Bioinformatics and Data Analysis in Microbiology 1st ed.; Bishop O.T.; Publisher: Caister Academic Press, UK, 2014; pp. 5180.
13. Escherichia coli MLST Database at http://mlst.warwick.ac.uk/mlst/dbs/Ecoli.
14. Bryant, J.; Chewapreecha, C.; Bentley, S.D. Developing insights into the mechanisms of evolution of bacterial pathogens from whole-genome
sequences. Future Microbiology 2012, 7(11), 1283–1296.
15. Aarestrup, F.M.; Brown, E.W.; Detter, C.; Gerner-Smidt, P.; Gilmour, M.W.; Harmsen, D.; Hendriksen, R.S.; Hewson, R.; Heymann, D.L.; Johansson,
K.; et al. Integrating genome-based informatics to modernize global disease monitoring, information sharing, and response. Emerg Infect Dis
2012, 18(11), e1.
16. Gault, G.; Weill, F.X.; Mariani-Kurkdjian, P.; Jourdan-da Silva, N.; King, L.; Aldabe, B.; Charron, M.; Ong, N.; Castor, C.; Mace, M.; et al. Outbreak
of haemolytic uraemic syndrome and bloody diarrhoea due to Escherichia coli O104:H4, south-west France, June 2011. Euro Surveill 2011,
16(26), 19905.
17. Frank, C.; Werber, D.; Cramer, J.P.; Askar, M.; Faber, M.; an der Heiden, M.; Fruth, A.; Prager, R.; Spode, A.; et al. Epidemic profile of Shiga-toxinproducing Escherichia coli O104:H4 outbreak in Germany. N Engl J Med 2011, 365(19), 1771-80.
18. Mellmann, A.; Harmsen, D.; Cummings, C.A.; Zentz, E.B.; Leopold, S.R.; Rico, A.; Prior, K.; Szczepanowski, R.; Ji, Y.; Zhang, W.; et al. Prospective
genomic characterization of the German enterohemorrhagic Escherichia coli O104:H4 outbreak by rapid next generation sequencing
technology. PLoS ONE 2011, 6, e22751.
19. Rasko, D.A.; Webster, D.R.; Sahl, J.W.; Bashir, A.; Boisen, N.; Scheutz, F.; Paxinos, E.E.; Sebra, R.; Chin, C.S.; Iliopoulos, D.; et al. Origins of the E.
coli strain causing an outbreak of hemolytic-uremic syndrome in Germany. N Engl J Med 2011, 365, 709-717.
20. Sherry, N.L.; Porter, J.L.; Seemann, T.; Watkins, A.; Stinear, T.P.; Howden, B.P. Outbreak investigation using high-throughput genome sequencing
within a diagnostic microbiology laboratory. J Clin Microbiol 2013, 51(5), 1396-401.
21. Underwood, A.P.; Dallman, T.; Thomson, N.R.; Williams, M.; Harker, K.; Perry, N.; Adak, B.; Willshaw, G.; Cheasty, T.; Green, J.; et al. Public
health value of next-generation DNA sequencing of enterohemorrhagic Escherichia coli isolates from an outbreak. J Clin Microbiol 2013,
51(1), 232-7.
22. Eyre, D.W.; Golubchik, T.; Gordon, N.C.; Bowden, R.; Piazza, P.; Batty, E.M.; Ip, C.L.; Wilson, D.J.; Didelot, X.; O'Connor, L.; et al. A pilot study
of rapid benchtop sequencing of Staphylococcus aureus and Clostridium difficile for outbreak detection and surveillance. BMJ Open 2012, 2,
e001124.
23. Parkinson, N.J.; Maslau, S.; Ferneyhough, B.; Zhang, G.; Gregory, L.; Buck, D.; Ragoussis, J.; Ponting, C.P.; Fischer, M.D. Preparation of highquality next-generation sequencing libraries from picogram quantities of target DNA. Genome Res 2012, 22(1), 125-33.
24. Koser, C.U.; Fraser, L.J.; Ioannou, A.; Becq, J.; Ellington, M.J.; Holden, M.T.; Reuter, S.; Török, M.E.; Bentley, S.D.; Parkhill, J.; et al. Rapid singlecolony whole-genome sequencing of bacterial pathogens J Antimicrob Chemother 2014, 69(5), 1275-81.
25. Quail, M.A.; Smith, M.; Jackson, D.; Leonard, S.; Skelly, T.; Swerdlow, H.P.; Gu, Y.; Ellis, P. SASI-Seq: sample assurance Spike-Ins, and highly
differentiating 384 barcoding for Illumina sequencing. BMC Genomics 2014, 15, 110, doi: 10.1186/1471-2164-15-110.
26. Lasken, R.S.; McLean, J.S. Recent advances in genomic DNA sequencing of microbial species from single cells. Nat Rev Genet 2014, 15(9), 577-84.
27. Gole, J.; Gore, A.; Richards, A.; Chiu, Y.J.; Fung, H.L.; Bushman, D.; Chiang, H.I.; Chun, J.; Lo, Y.H.; Zhang, K. Massively parallel polymerase
cloning and genome sequencing of single cells using nanoliter microwells. Nat Biotechnol 2013, 31(12), 1126-32.
28. Kim, K.E.; Peluso, P.; Baybayan, P.; Yeadon, P.J.; Yu, C.; Fisher, W.; Chin, C.S.; Rapicavoli, N.A.; Rank, D.R.; Li, J.; et al. Long-read, whole
genome shotgun sequence data from five model organisms. bioRXiv 2014, doi: http://dx.doi.org/10.1101/008037.
29. Chin, C.S.; Alexander, D.H.; Marks, P.; Klammer, A.A.; Drake, J.; Heiner, C.; Clum, A.; Copeland, A.; et al. Nonhybrid, finished microbial genome
assemblies from long-read SMRT sequencing data Nat Methods 2013, 10(6), 563-9.
30. Conlan, S.; Thomas, P.J.; Deming, C.; Park, M.; Lau, A.F.; Dekker, J.P.; Snitkin, E.S.; Clark, T.A.; Luong, K.; Song, Y.; et al. Single-molecule
sequencing to track plasmid diversity of hospital-associated carbapenemase-producing Enterobacteriaceae. Sci Transl Med 2014, 6(254),
254ra126.
31. Beatson, S.A.; Walker, M.J. Microbiology: Tracking antibiotic resistance. Science 2014, 345(6203), 1454-5.
32. Latif, H.; Li, H.J.; Charusanti, P.; Palsson, B.Ø.; Aziz, R.K. A Gapless, Unambiguous Genome Sequence of the Enterohemorrhagic Escherichia coli
O157:H7 Strain EDL933. Genome Announc 2014, 2(4), e00821-14.
33. Quick, J.; Quinlan, A.; Loman, N. A reference bacterial genome dataset generated on the MinION™ portable single-molecule nanopore sequencer.
bioRxiv 2014, doi: http://dx.doi.org/10.1101/009613.
34. Trecarichi, E.M.; Cauda, R.; Tumbarello, M. Detecting risk and predicting patient mortality in patients with extended-spectrum beta-lactamaseproducing Enterobacteriaceae bloodstream infections Future Microbiol 2012, 7, 1173-1189.
35. Salipante, S.J.; Roach, D.J.; Kitzman, J.O.; Snyder, M.W.; Stackhouse, B.; Butler-Wu, S.M.; Lee, C.; Cookson, B.T.; Shendure, J. Large-scale
genomic sequencing of extraintestinal pathogenic Escherichia coli strains. Genome Res. 2015, 25, 119-28.

12

36. Russo, T.A.; Johnson, J.R. Proposal for a new inclusive designation for extraintestinal pathogenic isolates of Escherichia coli: ExPEC. J Infect Dis
2000, 181, 1753-4.
37. Foxman, B. The epidemiology of urinary tract infection. Nat Rev Urol 2010, 7, 653-60.
38. Didelot, X.; Meric, G.; Falush, D.; Darling, A.E. Impact of homologous and non-homologous recombination in the genomic evolution of Escherichia
coli. BMC Genomics 2012, 13, 256.
39. Wiles, T.J.; Kulesus, R.R.; Mulvey, M.A. Origins and virulence mechanisms of uropathogenic Escherichia coli. Exp Mol Pathol 2008, 85, 11-19.
40. Wu, G.; Day, M.J.; Mafura, M.T.; Nunez-Garcia, J.; Fenner, J.J.; Sharma, M.; van, Essen-Zandbergen A.; Rodríguez, I.; Dierikx, C.; Kadlec, K.; et al.
Comparative analysis of ESBL-positive Escherichia coli isolates from animals and humans from the UK, The Netherlands and Germany. PLoS
One, 2013, 8(9), e75392.
41. Tango, C.N.; Mansur, A.R.; Oh, D.H. Fumaric Acid and Slightly Acidic Electrolyzed Water Inactivate Gram Positive and Gram Negative Foodborne
Pathogens. Microorganisms 2015, 3(1), 34-46. doi:10.3390/microorganisms3010034
42. Vincent, C.; Boerlin, P.; Daignault, D.; Dozois, C.M.; Dutil, L.; Galanakis, C.; Reid-Smith, R.J.; Tellier, P.P.; Tellis, P.A.; Ziebell, K.; et al. Food
reservoir for Escherichia coli causing urinary tract infections Emerg Infect Dis 2010, 16(1), 88-95.
43. Lupindu, A.M.; Olsen, J.E.; Ngowi, H.A.; Msoffe, P.L.; Mtambo, M.M.; Scheutz, F.; Dalsgaard, A. Occurrence and characterization of Shiga toxinproducing Escherichia coli O157:H7 and other non-sorbitol-fermenting E. coli in cattle and humans in urban areas of Morogoro, Tanzania.
Vector Borne Zoonotic Dis 2014, 14(7), 503-10.
44. Ewers, C.; Grobbel, M.; Stamm, I.; Kopp, P.A.; Diehl, I.; Semmler, T.; Fruth, A.; Beutlich, J.; Guerra, B.; Wieler, L.H.; et al. Emergence of human
pandemic O25:H4-ST131 CTX-M-15 extended-spectrum-beta-lactamase-producing Escherichia coli among companion animals. J Antimicrob
Chemother 2010, 65(4), 651-60.
45. Nebbia, P.; Tramuta, C.; Odore, R.; Nucera, D.; Zanatta, R.; Robino, P. Genetic and phenotypic characterisation of Escherichia coli producing
cefotaximase-type extended-spectrum beta-lactamases: first evidence of the ST131 clone in cats with urinary infections in Italy. J Feline Med
Surg 2014, doi: 10.1177/1098612X14527103.
46. Timofte, D.; Maciuca, I.E.; Kemmett, K.; Wattret, A.; Williams, N.J. Detection of the human-pandemic Escherichia coli B2-O25b-ST131 in UK dogs.
Vet Rec 2014, 174(14), 352. doi:10.1136/vr.101893.
47. Dahbi, G.; Mora, A.; López, C.; Alonso, M.P.; Mamani, R.; Marzoa, J.; Coira, A.; García-Garrote, F.; Pita, J.M.; Velasco, D.; et al. Emergence of new
variants of ST131 clonal group among extraintestinal pathogenic Escherichia coli producing extended-spectrum beta-lactamases. Int J
Antimicrob Agents 2013, 42, 347-351.
48. Izdebski, R.; Baraniak, A.; Fiett, J.; Adler, A.; Kazma, M.; Salomon, J.; Lawrence, C.; Rossini, A.; Salvia, A.; Vidal Samso, J.; et al. Clonal structure,
extended-spectrum beta-lactamases, and acquired AmpC-type cephalosporinases of Escherichia coli populations colonizing patients in
rehabilitation centers in four countries. Antimicrob Agents Chemother 2013, 57(1), 309-16
49. Matsumura, Y.; Yamamoto, M.; Higuchi, T.; Komori, T.; Tsuboi, F.; Hayashi, A.; Sugimoto, Y.; Hotta, G.; Matsushima, A.; Nagao, M.; et al.
Prevalence of plasmid-mediated AmpC beta-lactamase-producing Escherichia coli and spread of the ST131 clone among extended-spectrum
beta-lactamase-producing E. coli in Japan. Int J Antimicrob Agents 2012, 40(2), 158-62.
50. Johnson, J.R.; Urban, C.; Weissman, S.J.; Jorgensen, J.H.; Lewis, J.S.; Hansen, G.; Edelstein, P.H.; Robicsek, A.; Cleary, T.; Adachi, J.; et al.
Molecular epidemiological analysis of Escherichia coli sequence type ST131 (O25, H4) and blaCTX-M-15 among extended-spectrum-betalactamase-producing E. coli from the United States, 2000 to 2009. Antimicrob Agents Chemother 2012, 56(5), 2364-70.
51. Chen, L.F.; Freeman, J.T.; Nicholson, B.; Keiger, A.; Lancaster, S.; Joyce, M.; Woods, C.W.; Cook, E.; Adcock, L.; Louis, S.; et al. Widespread
dissemination of CTX-M-15 genotype extended-spectrum-beta-lactamase-producing enterobacteriaceae among patients presenting to
community hospitals in the southeastern United States. Antimicrob Agents Chemother 2014, 58(2), 1200-2.
52. Johnson, J.R.; Menard, M.; Johnston, B.; Kuskowski, M.A.; Nichol, K.; Zhanel, G.G. Epidemic clonal groups of Escherichia coli as a cause of
antimicrobial-resistant urinary tract infections in Canada, 2002 to 2004. Antimicrob Agents Chemother 2009, 53(7), 2733-9.
53. Fennell, J.; Vellinga, A.; Hanahoe, B.; Morris, D.; Boyle, F.; Higgins, F.; Lyons, M.; O'Connell, K.; Keady, D.; Cormican, M. Increasing prevalence
of ESBL production among Irish clinical Enterobacteriaceae from 2004 to 2008: an observational study. BMC Infect Dis 2012, 12, 116.
54. Clark, G.; Paszkiewicz, K.; Hale, J.; Weston, V.; Constantinidou, C.; Penn, C.; Achtman, M.; McNally, A. Genomic analysis uncovers a
phenotypically diverse but genetically homogeneous Escherichia coli ST131 clone circulating in unrelated urinary tract infections. J
Antimicrob Chemother 2012, 67(4), 868-77.
55. Rogers, B.A.; Sidjabat, H.E.; Paterson, D.L. Escherichia coli O25b-ST131: a pandemic, multiresistant, community-associated strain. J Antimicrob
Chemother 2011, 66, 1-14.
56. Woodford, N.; Ward, M.E.; Kaufmann, M.E.; Turton, J.; Fagan, E.J.; James, D.; Johnson, A.P.; Pike, R.; Warner, M.; Cheasty, T.; et al. Community
and hospital spread of Escherichia coli producing CTX-M extended-spectrum beta-lactamases in the UK. J Antimicrob Chemother 2004, 54,
735-743.
57. Escobar-Paramo, P.; Grenet, K.; Le Menac’h, A.; Rode, L.; Salgado, E.; Amorin, C.; Gouriou, S.; Picard, B.; Rahimy, M.C.; Andremont, A.; et al.
Large-scale population structure of human com- mensal Escherichia coli isolates. Appl Environ Microbiol 2004, 70, 5698-5700.
58. Escobar-Paramo, P.; Le Menac’h, A.; Le Gall, T.; Amorin, C.; Gouriou, S.; Picard, B.; Skurnik, D.; Denamur, E. Identification of forces shaping the
commensal Escherichia coli genetic structure by comparing animal and human isolates. Environ Microbiol Rep 2006, 8, 1975–1984.
59. Le Gall, T.; Clermont, O.; Gouriou, S.; Picard, B.; Nassif, X.; Denamur, E.; Tenaillon, O. Extraintestinal virulence is a coincidental by-product of
commensalism in B2 phylogenetic group Escherichia coli strains. Mol Biol Evol 2007, 24, 2373-2384.
60. Clermont, O.; Dhanji, H.; Upton, M.; Gibreel, T.; Fox, A.; Boyd, D.; Mulvey, M.R.; Nordmann, P.; Ruppe, E.; Sarthou, J.L.; et al. Rapid detection of
the O25b-ST131 clone of Escherichia coli encompassing the CTX-M-15- producing strains. J Antimicrob Chemother 2009, 64, 274-277.
61. Platell, J.L.; Johnson, J.R.; Cobbold, R.N.; Trott, D.J. Multidrug-resistant extraintestinal pathogenic Escherichia coli of sequence type ST131 in
animals and foods. Vet Microbiol 2011, 153(1-2), 99-108.
62. Zong, Z.; Yu, R. blaCTX-M-carrying Escherichia coli of the O25b ST131 clonal group have emerged in China. Diagn Microbiol Infect Dis 2011, 69,
228-31.
63. Olesen, B.; Hansen, D.S.; Nilsson, F.; Frimodt-Møller, J.; Leihof, R.F.; Struve, C.; Scheutz, F.; Johnston, B.; Krogfelt, K.A.; Johnson, J.R. Prevalence
and characteristics of the epidemic multiresistant Escherichia coli ST131 clonal group among extended-spectrum beta-lactamase-producing E.
coli isolates in Copenhagen, Denmark. J Clin Microbiol 2013, 51, 1779–1785.
64. Matsumura, Y.; Yamamoto, M.; Nagao, M.; Hotta, G.; Matsushima, A.; Ito, Y.; Takakura, S.; Ichiyama, S. Emergence and spread of B2-ST131-O25b,
B2-ST131-O16 and D-ST405 clonal groups among extended-spectrum-beta-lactamase-producing Escherichia coli in Japan. J Antimicrob
Chemother 2012, 67, 2612-2620.
65. Johnson, J.R.; Johnston, B.; Clabots, C.; Kuskowski, M.A.; Castanheira, M. Escherichia coli sequence type ST131 as the major cause of serious
multidrug-resistant E. coli infections in the United States 2007. Clin Infect Dis 2010, 51, 286-94.
66. Lau, S.H.; Kaufmann, M.E.; Livermore, D.M.; Woodford, N.; Willshaw, G.A.; Cheasty, T.; Stamper, K.; Reddy, S.; Cheesbrough, J.; Bolton, F.J.; et
al. UK epidemic Escherichia coli strains A-E, with CTX-M-15 beta-lactamase, all belong to the international O25:H4-ST131 clone. J
Antimicrob Chemother 2008, 62, 1241-4.
67. Alobwede, I.; M'Zali, F.H.; Livermore, D.M.; Heritage, J.; Todd, N.; Hawkey, P.M. CTX-M extended-spectrum beta-lactamase arrives in the UK. J
Antimicrob Chemother. 2003, 51(2), 470-1.

13

68. Olesen, B.; Frimodt-Møller, J.; Leihof, RF.; Struve, C.; Johnston, B.; Hansen, D.S.; Scheutz, F.; Krogfelt, K.A.; Kuskowski, M.A.; Clabots, C.;
Johnson, J.R. Temporal trends in antimicrobial resistance and virulence-associated traits within the Escherichia coli sequence type 131 clonal
group and its H30 and H30-Rx subclones, 1968 to 2012. Antimicrob Agents Chemother. 2014, 58, 6886-95.
69. Huttner, A.; Harbarth, S.; Carlet, J.; Cosgrove, S.; Goossens, H.; Holmes, A.; Jarlier, V.; Voss, A.; Pittet, D. Antimicrobial resistance: a global view
from the 2013 World Healthcare-Associated Infections Forum. Antimicrob Resist Infect Control. 2013, 2, 31.
70. Gupta, K.; Scholes, D.; Stamm, W.E. Increasing prevalence of antimicrobial resistance among uropathogens causing acute uncomplicated cystitis in
women JAMA 1999, 281, 736-738.
71. Andersson, D.I.; Hughes, D. Evolution of antibiotic resistance at non-lethal drug concentrations. Drug Resist Updat 2012, 15(3), 162-72.
72. Oz, T.; Guvenek, A.; Yildiz, S.; Karaboga, E.; Tamer, Y.T.; Mumcuyan, N.; Ozan, V.B.; Senturk, G.H.; Cokol, M.; Yeh, P.; et al. Strength of selection
pressure is an important parameter contributing to the complexity of antibiotic resistance evolution. Mol Biol Evol 2014, 31(9), 2387-401.
73. Harris, S.; Morris, C.; Morris, D.; Cormican, M.; Cummins, E. The effect of hospital effluent on antimicrobial resistant E. coli within a municipal
wastewater system. Environ Sci Process Impacts 2013, 15(3), 617-22.
74. Galvin, S.; Boyle, F.; Hickey, P.; Vellinga, A.; Morris, D.; Cormican, M. Enumeration and characterization of antimicrobial-resistant Escherichia coli
bacteria in effluent from municipal, hospital, and secondary treatment facility sources. Appl Environ Microbiol 2010, 76(14), 4772-9.
75. Udikovic-Kolic, N.; Wichmann, F.; Broderick, N.A.; Handelsman, J. Bloom of resident antibiotic-resistant bacteria in soil following manure
fertilization. Proc Natl Acad Sci U S A 2014, 111(42), 15202-7.
76. Currie, C.J.; Berni, E.; Jenkins-Jones, S.; Poole, C.D.; Ouwens, M.; Driessen, S.; de Voogd, H.; Butler, C.C.; Morgan, C.L. Antibiotic treatment failure
in four common infections in UK primary care 1991-2012: longitudinal analysis. BMJ 2014, 349, g5493.
77. Morris, D.; Boyle, F.; Buckley, V.; Xu, L.; Hanahoe, B.; Hawkey, P.; Cormican, M. CTX-M enzymes are the predominant extended-spectrum betalactamases produced by Enterobacteriaceae in Ireland. J Antimicrob Chemother 2009, 64(4), 864-866.
78. Morris, D.; McGarry, E.; Cotter, M.; Passet, V.; Lynch, M.; Ludden, C.; Hannan, M.M.; Brisse, S.; Cormican, M. Detection of OXA-48
carbapenemase in the pandemic clone Escherichia coli O25b:H4-ST131 in the course of investigation of an outbreak of OXA-48-producing
Klebsiella pneumoniae. Antimicrob Agents Chemother 2012, 56(7), 4030-1.
79. Agabou, A.; Pantel, A.; Ouchenane, Z.; Lezzar, N.; Khemissi, S.; Satta, D.; Sotto, A.; Lavigne, J.P. First description of OXA-48-producing
Escherichia coli and the pandemic clone ST131 from patients hospitalised at a military hospital in Algeria. Eur J Clin Microbiol Infect Dis
2014, 33(9), 1641-6.
80. Cai, J.C.; Zhang, R.; Hu, Y.Y.; Zhou, H.W.; Chen, G.X. Emergence of Escherichia coli sequence type 131 isolates producing KPC-2 carbapenemase
in China. Antimicrob Agents Chemother 2014, 58(2), 1146-52.
81. Morris, D.; Boyle, F.; Ludden, C.; Condon, I.; Hale, J.; O'Connell, N.; Power, L.; Boo, T.W.; Dhanji, H.; Lavallee, C.; et al. Production of KPC-2
carbapenemase by an Escherichia coli clinical isolate belonging to the international ST131 clone. Antimicrob Agents Chemother 2011, 55(10),
4935-6.
82. Riley, L.W. Pandemic lineages of extraintestinal pathogenic Escherichia coli. Clin Microbiol Infect 2014, 20(5), 380-90.
83. Karami, N.; Helldal, L.; Welinder-Olsson, C.; Ahrén, C.; Moore, E.R. Sub-typing of extended-spectrum-beta-lactamase-producing isolates from a
nosocomial outbreak: application of a 10-loci generic Escherichia coli multi-locus variable number tandem repeat analysis. PLoS One 2013,
8(12), e83030.
84. Shakir, S.M.; Goldbeck, J.M.; Robison, D.; Eckerd, A.M.; Chavez-Bueno, S. Genotypic and Phenotypic Characterization of Invasive Neonatal
Escherichia coli Clinical Isolates. Am J Perinatol 2014, doi: 10.1055/s-0034-1370341.
85. Giuffrè, M.; Cipolla, D.; Bonura, C.; Geraci, D.M.; Aleo, A.; Di Noto, S.; Nociforo, F.; Corsello, G.; Mammina, C. Outbreak of colonizations by
extended-spectrum beta-lactamase-producing Escherichia coli sequence type 131 in a neonatal intensive care unit, Italy. Antimicrob Resist
Infect Control. 2013, 2(1), 8.
86. Blanco, J.; Mora, A.; Mamani, R.; Lopez, C.; Blanco, M.; Dahbi, G.; Herrera, A.; Marzoa, J.; Fernandez, V.; de la Cruz, F.; et al. Four main virotypes
among extended-spectrum-beta-lactamase-producing isolates of Escherichia coli O25b:H4-B2-ST131: bacterial, epidemiological, and clinical
characteristics. J Clin Microbiol 2013, 51, 3358-3367, doi: 10.1128/JCM.01555-13.
87. Banerjee, R.; Johnston, B.; Lohse, C.; Porter, S.B.; Clabots, C.; Johnson, J.R. Escherichia coli sequence type 131 is a dominant, antimicrobial-resistant
clonal group associated with healthcare and elderly hosts. Infect Control Hosp Epidemiol 2013, 34(4), 361-9.
88. Livermore, D.M.; Woodford, N. The beta-lactamase threat in Enterobacteriaceae, Pseudomonas and Acinetobacter. Trends Microbiol 2006, 14(9),
413-20.
89. Pelly, H.; O’Connell, E.; Hanahoe, B.; Chambers, C.; Biernacka, K.; Gray, S.; Cormican, M. Outbreak of extended spectrum beta-lactamase producing
E. coli in a nursing home in Ireland, May 2006. Euro Surveill 2006, 11(8), E060831.
90. Burke, L.; Humphreys, H.; Fitzgerald-Hughes, D. The revolving door between hospital and community: extended-spectrum beta-lactamase-producing
Escherichia coli in Dublin. J Hosp Infect 2012, 81(3), 192-8.
91. Pitout, J.D.; Gregson, D.B.; Campbell, L.; Laupland, K.B. Molecular characteristics of extended-spectrum-beta-lactamase-producing Escherichia coli
isolates causing bacteremia in the Calgary Health Region from 2000 to 2007: emergence of clone ST131 as a cause of community-acquired
infections. Antimicrob Agents Chemother 2009, 53(7), 2846-51.
92. Suetens, C. Healthcare-associated infections in European long-term care facilities: how big is the challenge? Euro Surveill. 2012, 17, 20259.
93. Peirano, G.; Pitout, J.D.D. Molecular epidemiology of Escherichia coli producing CTX-M b-lactamases: the worldwide emergence of clone ST131
O25:H4. Int J Antimicrob Agents 2010, 35, 316-321.
94. Van Tonder, A.J.; Mistry, S.; Bray, J.E.; Hill, D.M.; Cody, A.J.; Farmer, C.L.; Klugman, K.P.; von Gottberg, A.; Bentley, S.D.; Parkhill, J.; et al.
Defining the estimated core genome of bacterial populations using a Bayesian decision model. PLoS Comput Biol 2014, 10(8), e1003788.
95. Hooper, S.D.; Berg, O.G. Duplication is more common among laterally transferred genes than among indigenous genes. Genome Biol 2003, 4, R48.
96. McNally, A.; Cheng, L.; Harris, S.R.; Corander, J. The evolutionary path to extraintestinal pathogenic, drug-resistant Escherichia coli is marked by
drastic reduction in detectable recombination within the core genome. Genome Biol Evol 2013, 5(4), 699-710.
97. Rasko, D.A.; Rosovitz, M.J.; Myers, G.S.; Mongodin, E.F.; Fricke, W.F.; Gajer, P.; Crabtree, J.; Sebaihia, M.; Thomson, N.R.; Chaudhuri, R.; et al.
The pangenome structure of Escherichia coli: comparative genomic analysis of Escherichia coli commensal and pathogenic isolates. J
Bacteriol 2008, 190, 6881-6893.
98. Price, L.B.; Johnson, J.R.; Aziz, M.; Clabots, C.; Johnston, B.; Tchesnokova, V.; Nordstrom, L.; Billig, M.; Chattopadhyay, S.; Stegger, M.; et al. The
epidemic of extended-spectrum-beta-lactamase-producing Escherichia coli ST131 is driven by a single highly pathogenic subclone, H30-Rx.
MBio 2013, 4(6), e00377-13.
99. Treangen, T.J.; Rocha, E.P. Horizontal transfer, not duplication, drives the expansion of protein families in prokaryotes PLoS Genet 2011, 7,
e1001284.
100. Bobay, L.M.; Touchon, M.; Rocha, E.P. Pervasive domestication of defective prophages by bacteria. Proc Natl Acad Sci U S A 2014, 111(33),
12127-32.
101. Näsvall, J.; Sun, L.; Roth, J.R.; Andersson, D.I. Real-time evolution of new genes by innovation, amplification, and divergence. Science 2012,
338(6105), 384-7.
102. Bobay, L.M.; Rocha, E.P.; Touchon, M. The adaptation of temperate bacteriophages to their host genomes. Mol Biol Evol 2013, 30(4), 737-51.
103. Waldor, M.K.; Friedman, D.I. Phage regulatory circuits and virulence gene expression. Curr Opin Microbiol 2005, 8(4), 459-65.
104. Edlin, G.; Lin, L.; Bitner, R. Reproductive fitness of P1, P2, and Mu lysogens of Escherichia coli. J Virol 1977, 21(2), 560-4.

14

105. Rabinovich, L.; Sigal, N.; Borovok, I.; Nir-Paz, R.; Herskovits, A.A. Prophage excision activates Listeria competence genes that promote
phagosomal escape and virulence. Cell 2012, 150(4), 792-802.
106. Wang, X.; Kim, Y.; Ma, Q.; Hong, S.H.; Pokusaeva, K.; Sturino, J.M.; Wood, T.K. Cryptic prophages help bacteria cope with adverse environments.
Nat Commun 2010, 1, 147.
107. Gödeke, J.; Paul, K.; Lassak, J.; Thormann, K.M. Phage-induced lysis enhances biofilm formation in Shewanella oneidensis MR-1. ISME J 2011,
5(4), 613-26.
108. Wozniak, R.A.; Fouts, D.E.; Spagnoletti, M.; Colombo, M.M.; Ceccarelli, D.; Garriss, G.; Déry, C.; Burrus, V.; Waldor, M.K. Comparative ICE
genomics: insights into the evolution of the SXT/R391 family of ICEs. PLoS Genet 2009, 5, e1000786. doi:10.1371/journal.pgen.1000786.
109. D’Agata, E.M.; Dupont-Rouzeyrol, M.; Magal, P.; Olivier, D.; Ruan, S. The impact of different antibiotic regimens on the emergence of
antimicrobial-resistant bacteria. PLoS One 2008, 3(12), e4036.
110. Palmer, A.C.; Kishony, R. Opposing effects of target overexpression reveal drug mechanisms. Nat Commun 2014, 5, 4296.
111. Avasthi, T.S.; Kumar, N.; Baddam, R.; Hussain, A.; Nandanwar, N.; Jadhav, S.; Ahmed, N. Genome of multidrug-resistant uropathogenic
Escherichia coli strain NA114 from India J Bacteriol 2011, 193(16), 4272-3.
112. Andersen, P.S.; Stegger, M.; Aziz, M.; Contente-Cuomo, T.; Gibbons, H.S.; Keim, P.; Sokurenko, E.V.; Johnson, J.R.; Price, L.B. Complete Genome
Sequence of the Epidemic and Highly Virulent CTX-M-15-Producing H30-Rx Subclone of Escherichia coli ST131. Genome Announc 2013,
1(6),e00988-13.
113. Forde, B.M.; Zakour, B.; Stanton-Cook, M.; Phan, M.D.; Totsika, M.; Peters, K.M.; Chan, K.G.; Schembri, M.A.; Upton, M.; Beatson, S.A. The
Complete Genome Sequence of Escherichia coli EC958: A High Quality Reference Sequence for the Globally Disseminated Multidrug
Resistant E. coli O25b:H4-ST131 Clone. PLoS One 2014, 9(8), e104400.
114. Totsika, M.; Beatson, S.A.; Sarkar, S.; Phan, M.D.; Petty, N.K.; Bachmann, N.; Szubert, M.; Sidjabat, H.E.; Paterson, D.L.; Upton, M.; et al. Insights
into a multidrug resistant Escherichia coli pathogen of the globally disseminated ST131 lineage: genome analysis and virulence mechanisms.
PLoS One 2011, 6(10), e26578.
115. Clermont, O.; Lavollay, M.; Vimont, S.; Deschamps, C.; Forestier, C.; Branger, C.; Denamur, E.; Arlet, G. The CTX-M-15-producing Escherichia
coli diffusing clone belongs to a highly virulent B2 phylogenetic subgroup. J Antimicrob Chemother 2008, 61, 1024-8.
116. Petty, N.K.; Zakour, B.; Stanton-Cook, M.; Skippington, E.; Totsika, M.; Forde, B.M.; Phan, M.D.; Moriel, DG.; Peters, K.M.; Davies, M.; et al.
Global dissemination of a multidrug resistant Escherichia coli clone. Proc Natl Acad Sci U S A 2014, 111(15), 5694-9.
117. Peirano, G.; Bradford, P.A.; Kazmierczak, K.M.; Badal, R.E.; Hackel, M.; Hoban, D.J.; Pitout, J.D. Global Incidence of Carbapenemase-Producing
Escherichia coli ST131. Emerg Infect Dis 2014, 20(11), 1928-31.
118. Peirano, G.; van der Bij, A.K.; Freeman, J.L.; Poirel, L.; Nordmann, P.; Costello, M.; Tchesnokova, V.L.; Pitout, J.D. Characteristics of Escherichia
coli sequence type 131 isolates that produce extended-spectrum beta-lactamases: global distribution of the H30-Rx sublineage. Antimicrob
Agents Chemother. 2014, 58(7), 3762-7.
119. Cantón, R.; Coque, T.M. The CTX-M beta-lactamase pandemic. Curr Opin Microbiol 2006, 9(5), 466-75.
120. Peirano, G.; Pitout, J.D. Fluoroquinolone-resistant Escherichia coli sequence type 131 isolates causing bloodstream infections in a Canadian region
with a centralized laboratory system: rapid emergence of the H30-Rx sublineage. Antimicrob Agents Chemother 2014, 58(5), 2699-703.
121. Rooney, P.J.; O'Leary, M.C.; Loughrey, A.C.; McCalmont, M.; Smyth, B.; Donaghy, P.; Badri, M.; Woodford, N.; Karisik, E.; Livermore, D.M.
Nursing homes as a reservoir of extended-spectrum beta-lactamase (ESBL)-producing ciprofloxacin-resistant Escherichia coli. J Antimicrob
Chemother 2009, 64(3), 635-41.
122. Banerjee, R.; Johnson, J.R. Escherichia coli ST131: variations on a theme of clonal expansion. Enferm Infecc Microbiol Clin 2013, 31, 355-356.
123. Gullberg, E.; Cao, S.; Berg, O.G.; Ilbäck, C.; Sandegren, L.; Hughes, D.; Andersson, D.I. Selection of resistant bacteria at very low antibiotic
concentrations. PLoS Pathog 2011, 7, e1002158.
124. Adams-Sapper, S.; Diep, B.A.; Perdreau-Remington, F.; Riley, L.W. Clonal composition and community clustering of drug-susceptible and -resistant
Escherichia coli isolates from bloodstream infections. Antimicrob Agents Chemother 2013, 57(1), 490-7.
125. Johnson, J.R.; Murray, A.C.; Gajewski, A.; Sullivan, M.; Snippes, P.; Kuskowski, M.A.; Smith, K.E. Isolation and molecular characterization of
nalidixic acid-resistant extraintestinal pathogenic Escherichia coli from retail chicken products. Antimicrob Agents Chemother 2003, 47, 21612168.
126. Pitout, J.D. Extraintestinal Pathogenic Escherichia coli: A Combination of Virulence with Antibiotic Resistance. Front Microbiol 2012, 3, 9.
127. Nicolas-Chanoine, M.H.; Bertrand, X.; Madec, J.Y. Escherichia coli ST131, an intriguing clonal group. Clin Microbiol Rev 2014, 27(3), 543-74.
128. Dhanji, H.; Doumith, M.; Rooney, P.J.; O’Leary, M.C.; Loughrey, A.C.; Hope, R.; Woodford, N.; Livermore, D.M. Molecular epidemiology of
fluoroquinolone-resistant ST131 Escherichia coli producing CTX-M extended-spectrum beta-lactamases in nursing homes in Belfast, UK. J.
Antimicrob. Chemother. 2011, 66, 297–303.
129. Bush, K.; Jacoby, G.A. Updated functional classification of beta-lactamases. Antimicrobial Agents and Chemotherapy 2010, 54(3), 969–976.
130. Jensen, L.B.; Hasman, H.; Agersø, Y.; et al. First description of an oxyiminocephalosporin-resistant, ESBL-carrying Escherichia coli isolated from
meat sold in Denmark. J Antimicrob Chemother 2006, 57, 793–4.
131. Cloeckaert, A.; Praud, K.; Doublet, B.; et al. Dissemination of an extended-spectrum-b-lactamase blaTEM-52 gene-carrying IncI1 plasmid in various
Salmonella enterica serovars isolated from poultry and humans in Belgium and France between 2001 and 2005. Antimicrob Agents Chemother
2007, 51, 1872–5.
132. Yong, D.; Toleman, M.A.; Giske, C.G.; Cho, H.S.; Sundman, K.; Lee, K.; Walsh, T.R. Characterization of a new metallo-beta-lactamase gene,
bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from
India. Antimicrob Agents Chemother 2009, 53(12), 5046-54
133. Naas, T.; Cuzon, G.; Gaillot, O.; Courcol, R.; Nordmann, P. When carbapenem-hydrolyzing beta-lactamase KPC meets Escherichia coli ST131 in
France. Antimicrob Agents Chemother 2011, 55, 4933-4934.
134. Kim, Y.A.; Qureshi, Z.A.; Adams-Haduch, J.M.; Park, Y.S.; Shutt, K.A.; Doi, Y. Features of infections due to Klebsiella pneumoniae
carbapenemase-producing Escherichia coli: emergence of sequence type 131. Clin Infect Dis 2012, 55, 224-231.
135. Mantengoli, E.; Luzzaro, F.; Pecile, P.; Cecconi, D.; Cavallo, A.; Attala, L.; Bartoloni, A.; Rossolini, G.M. Escherichia coli ST131 producing
extended-spectrum beta-lactamases plus VIM-1 carbapenemase: further narrowing of treatment options. Clin Infect Dis 2011, 52(5), 690-1.
136. Yan, J.-.J.; Tsai, L.-.H.; Wu, J.-.J. Emergence of the IMP-8 metallo-beta-lactamase in the Escherichia coli ST131 clone in Taiwan. Int J Antimicrob
Agents 2012, 40, 281-282.
137. Peirano, G.; Schreckenberger, P.C.; Pitout, J.D. Characteristics of NDM-1-producing Escherichia coli isolates that belong to the successful and
virulent clone ST131. Antimicrob Agents Chemother 2011, 55(6), 2986-8.
138. Seema, K.; Ranjan Sen, M.; Upadhyay, S.; Bhattacharjee, A. Dissemination of the New Delhi metallo-beta-lactamase-1 (NDM-1) among
Enterobacteriaceae in a tertiary referral hospital in north India. J Antimicrob Chemother 2011, 66(7), 1646-7.
139. Deshpande, P.; Rodrigues, C.; Shetty, A.; Kapadia, F.; Hedge, A.; Soman, R. New Delhi Metallo-beta lactamase (NDM-1) in Enterobacteriaceae:
treatment options with carbapenems compromised. J Assoc Physicians India 2010, 58, 147-9.
140. Perry, J.D.; Naqvi, S.H.; Mirza, I.A.; Alizai, S.A.; Hussain, A.; Ghirardi, S.; Orenga, S.; Wilkinson, K.; Woodford, N.; Zhang, J.; et al. Prevalence of
faecal carriage of Enterobacteriaceae with NDM-1 carbapenemase at military hospitals in Pakistan, and evaluation of two chromogenic media.
J Antimicrob Chemother 2011, 66, 2288-2294.

15

141. Bonnin, R.A.; Poirel, L.; Carattoli, A.; Nordmann, P. Characterization of an IncFII plasmid encoding NDM-1 from Escherichia coli ST131. PLoS
One. 2012 7(4), e34752.
142. Gaillot, O.; Clement, C.; Simonet, M.; Philippon, A. Novel transferable beta-lactam resistance with cephalosporinase characteristics inSalmonella
enteritidis. J Antimicrob Chemother 1997, 39, 85–87.
143. Naseer, U.; Olsson-Liljequist, B.E.; Woodford, N.; Dhanji, H.; Canton, R.; Sundsfjord, A.; Lindstedt, B.A. Multi-locus variable number of tandem
repeat analysis for rapid and accurate typing of virulent multi- drug resistant Escherichia coli clones. PLoS One 2012, 7, e41232.
144. Sousa, A.; Magalhães, S.; Gordo, I. Cost of antibiotic resistance and the geometry of adaptation. Mol Biol Evol 2012, 29(5), 1417-28.
145. LeClerc, J.E.; Li, B.G.; Payne, W.L.; Cebula, T.A. High mutation frequencies among Escherichia coli and Salmonella pathogens. Science 1996, 274,
1208-1211.
146. Olofsson, S.K.; Geli, P.; Andersson, D.I.; Cars, O. Pharmacodynamic model to describe the concentration-dependent selection of cefotaximeresistant Escherichia coli. Antimicrob Agents Chemother 2005, 49, 5081–5091.
147. Silva, R.F.; Mendonça, S.C.; Carvalho, L.M.; Reis, A.M.; Gordo, I.; Trindade, S.; Dionisio, F. Pervasive sign epistasis between conjugative plasmids
and drug-resistance chromosomal mutations. PLoS Genet 2011, 7(7), e1002181.
148. Trindade, S.; Sousa, A.; Xavier, K.B.; Dionisio, F.; Ferreira, M.G.; Gordo, I. Positive epistasis drives the acquisition of multidrug resistance. PLoS
Genet 2009, 5(7), e1000578.
149. Morgand, M.; Vimont, S.; Bleibtreu, A.; Boyd, A.; Thien, H.V.; Zahar, J.R.; Denamur, E.; Arlet, G. Extended-spectrum beta-lactamase-producing
Escherichia coli infections in children: Are community-acquired strains different from nosocomial strains? Int J Med Microbiol 2014, doi:
10.1016/j.ijmm.2014.06.003.
150. Leflon-Guibout, V.; Blanco, J.; Amaqdouf, K.; Mora, A.; Guize, L.; Nicolas-Chanoine, M.H. Absence of CTX-M enzymes but high prevalence of
clones, including clone ST131, among fecal Escherichia coli isolates from healthy subjects living in the area of Paris, France. J Clin Microbiol
2008, 46, 3900-3905.
151. Angst, D.C.; Hall, A.R. The cost of antibiotic resistance depends on evolutionary history in Escherichia coli. BMC Evol Biol 2013, 13, 163.
152. Kawamura, K.; Goto, K.; Nakane, K.; Arakawa, Y. Molecular epidemiology of extended-spectrum beta-lactamases and Escherichia coli isolated
from retail foods including chicken meat in Japan. Foodborne Pathog Dis 2014, 11(2), 104-10.
153. Randall, L.P.; Clouting, C.; Horton, R.A.; Coldham, N.G.; Wu, G.; Clifton-Hadley, F.A.; Davies, R.H.; Teale, C.J. Prevalence of Escherichia coli
carrying extended-spectrum beta-lactamases (CTX-M and TEM-52) from broiler chickens and turkeys in Great Britain between 2006 and 2009.
J Antimicrob Chemother. 2011 66(1), 86-95.
154. Kutumbaka, K.K.; Han, S.; Mategko, J.; Nadala, C.; Buser, G.L.; Cassidy, M.P.; Beldavs, Z.G.; Weissman, S.J.; Morey, K.E.; Vega, R.; Samadpour,
M. Draft Genome Sequence of blaNDM-1-Positive Escherichia coli O25b-ST131 Clone Isolated from an Environmental Sample. Genome
Announc. 2014, 2(3).
155. Morar, M.; Wright, G.D. The genomic enzymology of antibiotic resistance. Annu Rev Genet 2010, 44, 25-51.
156. Soo, V.W.; Hanson-Manful, P.; Patrick, W.M. Artificial gene amplification reveals an abundance of promiscuous resistance determinants in
Escherichia coli. Proc Natl Acad Sci U S A 2011, 108(4), 1484-9.
157. Rodrigo, G.; Baji´c, D.; Elola, I.; Poyatos, J.F. Dual autogenous control of the multiple antibiotic resistance phenotype in Escherichia coli. bioRxiv
doi: http://dx.doi.org/10.1101/008169.
158. Ravva, S.V.; Cooley, M.B.; Sarreal, C.Z.; Mandrell, R.E. Fitness of Outbreak and Environmental Strains of Escherichia coli O157:H7 in
Aerosolizable Soil and Association of Clonal Variation in Stress Gene Regulation. Pathogens 2014, 3(3), 528-548.
159. Imming, P.; Sinning, C.; Meyer, A. Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov 2006, 5, 821-834.
160. Wilkinson, D.J. Stochastic modelling for quantitative description of heterogeneous biological systems. Nature Rev Genet 2009, 10, 122-133.
161. Ferguson, M.L.; Le Coq, D.; Jules, M.; Aymerich, S.; Radulescu, O.; Declerck, N.; Royer, C.A. Reconciling molecular regulatory mechanisms with
noise patterns of bacterial metabolic promoters in induced and repressed states. Proc Natl Acad Sci U S A 2012, 109(1), 155-60.
162. Wolf, L.; Silander, O.K.; van Nimwegen, EJ. Expression noise facilitates the evolution of gene regulation. bioRxiv doi:
http://dx.doi.org/10.1101/007237.
163. Cheng, A.A.; Dinge, H.; Lu, T.K. Enhanced killing of antibiotic-resistant bacteria enabled by massively parallel combinatorial genetics. Proc Natl
Acad Sci U S A 2014, 111, 12462–12467.
164. Silander, O.K.; Nikolic, N.; Zaslaver, A.; Bren, A.; Kikoin, I.; Alon, U.; Ackermann, M. A genome-wide analysis of promoter-mediated phenotypic
noise in Escherichia coli. PLoS Genet 2012, 8(1), e1002443.
165. Bollenbach, T.; Kishony, R. Resolution of gene regulatory conflicts caused by combinations of antibiotics. Mol Cell 2011, 42(4), 413-25.
166. Caroff, N.; Espaze, E.; Gautreau, D.; Richet, H.; Reynaud, A. Analysis of the effects of -42 and -32 ampC promoter mutations in clinical isolates of
Escherichia coli hyperproducing ampC. J Antimicrob Chemother 2000, 45, 783-788.
167. Teichmann, S.A.; Babu, M.M. Gene regulatory network growth by duplication. Nat Genet 2004, 36(5), 492-6.
168. Toprak, E.; Veres, A.; Michel, J.B.; Chait, R.; Hartl, D.L.; Kishony, R. Evolutionary paths to antibiotic resistance under dynamically sustained drug
selection. Nat Genet 2011, 44(1), 101-5.
169. Thomas, R. Laws for the dynamics of regulatory networks. Int J Dev Biol 1998, 42(3), 479-85.
170. Kim, S.; Lieberman, T.D.; Kishony, R. Alternating antibiotic treatments constrain evolutionary paths to multidrug resistance. Proc Natl Acad Sci U S
A 2014, 111(40), 14494-9.
171. Adler, M.; Anjum, M.; Andersson, D.I.; Sandegren, L. Influence of acquired beta-lactamases on the evolution of spontaneous carbapenem resistance
in Escherichia coli. J Antimicrob Chemother 2013, 68(1), 51-9.
172. Raeside, C.; Gaffé, J.; Deatherage, D.E.; Tenaillon, O.; Briska, A.M.; Ptashkin, R.N.; Cruveiller, S.; Médigue, C.; Lenski, R.E.; Barrick, J.E.; et al.
Large chromosomal rearrangements during a long-term evolution experiment with Escherichia coli. MBio 2014, 5(5), e01377-14.
173. Aldridge, B.B.; Fernandez-Suarez, M.; Heller, D.; Ambravaneswaran, V.; Irimia, D.; Toner, M.; Fortune, S.M. Asymmetry and aging of
mycobacterial cells lead to variable growth and antibiotic susceptibility. Science 2012, 335(6064), 100-4.
174. Klumpp, S.; Zhang, Z.; Hwa, T. Growth rate-dependent global effects on gene expression in bacteria. Cell 2009,139, 1366-1375.
175. Elowitz, M.B.; Levine, A.J.; Siggia, E.D.; Swain, P.S. Stochastic gene expression in a single cell. Science 2002, 297, 1183-1186.
176. Balaban, N.Q.; Merrin, J.; Chait, R.; Kowalik, L.; Leibler, S. Bacterial persistence as a phenotypic switch. Science 2004, 305(5690), 1622-5.
177. Fasani, R.A.; Savageau, M.A. Molecular mechanisms of multiple toxin-antitoxin systems are coordinated to govern the persister phenotype. Proc
Natl Acad Sci U S A 2013, 110(27), E2528-37.
178. Fridman, O.; Goldberg, A.; Ronin, I.; Shoresh, N.; Balaban, N.Q. Optimization of lag time underlies antibiotic tolerance in evolved bacterial
populations. Nature 2014, 513(7518), 418-21.
179. Lou, C.; Li, Z.; Ouyang, Q. A molecular model for persister in E. coli. J Theor Biol 2008, 255(2), 205-9.
180. Grundmann, H. Towards a global antibiotic resistance surveillance system: a primer for a roadmap. Ups J Med Sci 2014, 119(2), 87-95.
181. Li, L.M.; Grassly, N.C.; Fraser, C. Genomic analysis of emerging pathogens: methods, application and future trends. Genome Biol. 2014, 15, 541.
182. Joensen, K.G.; Scheutz, F.; Lund, O.; Hasman, H.; Kaas, R.S.; Nielsen, E.M.; Aarestrup, F.M. Real-time whole-genome sequencing for routine
typing, surveillance, and outbreak detection of verotoxigenic Escherichia coli. J Clin Microbiol 2014, 52(5), 1501-10.
183. Caboche, S.; Audebert, C.; Hot, D. High-Throughput Sequencing, a Versatile Weapon to Support Genome-Based Diagnosis in Infectious Diseases:
Applications to Clinical Bacteriology. Pathogens 2014, 3, 258-279.

16

184. Croucher, N.J.; Harris, S.R.; Fraser, C.; Quail, M.A.; Burton, J.; van der Linden, M.; McGee, L.; von Gottberg, A.; Song, J.H.; Ko, K.S.; et al. Rapid
pneumococcal evolution in response to clinical interventions. Science 2011, 331(6016), 430-4.
185. Alqasim, A.; Scheutz, F.; Zong, Z.; McNally, A. Comparative genome analysis identifies few traits unique to the Escherichia coli ST131 H30Rx
clade and extensive mosaicism at the capsule locus. BMC Genomics 2014, 15(1), 830
186. Yahara, K.; Furuta, Y.; Oshima, K.; Yoshida, M.; Azuma, T.; Hattori, M.; Uchiyama, I.; Kobayashi, I. Chromosome painting in silico in a bacterial
species reveals fine population structure. Mol Biol Evol 2013, 30(6), 1454-64.
187. Yahara, K.; Didelot, X.; Ansari, M.A.; Sheppard, S.K.; Falush, D. Efficient inference of recombination hot regions in bacterial genomes. Mol Biol
Evol 2014, 31(6), 1593-605.
188. Shimodaira, H. An approximately unbiased test of phylogenetic tree selection. Syst Biol 2002, 51(3), 492–508.
189. Schierup, M.H. Consequences of recombination on traditional phylogenetic analysis. Genetics 2000, 156, 879-891.
190. Barrick, J.E.; Kauth, M.R.; Strelioff, C.C.; Lenski, R.E. Escherichia coli rpoB mutants have increased evolvability in proportion to their fitness
defects. Mol Biol Evol 2010, 27, 1338-1347.
191. Pybus, O.G.; Rambaut, A.; Belshaw, R.; Freckleton, R.P.; Drummond, A.J.; Holmes, E.C. Phylogenetic evidence for deleterious mutation load in
RNA viruses and its contribution to viral evolution. Mol Biol Evol 2007, 24(3), 845-52.
192. Neher, R.A.; Russell, C.A.; Shraiman, B.I. Predicting evolution from the shape of genealogical trees. Arxiv doi: arXiv:1406.0789v2.
193. Dobrindt, U. (Patho-)Genomics of Escherichia coli. Int J Med Microbiol 2005, 295(6-7), 357-71.
194. Freeman, J.T.; McBride, S.J.; Heffernan, H.; Bathgate, T.; Pope, C.; Ellis-Pegler, R.B. Community-onset genitourinary tract infection due to CTX-M15-Producing Escherichia coli among travelers to the Indian subcontinent in New Zealand. Clinical Infectious Diseases 2008, 47(5), 689–692.
195. Laupland, K.B.; Church D.L.; Vidakovich, J.; Mucenski, M.; Pitout, J.D. Community-onset extended-spectrum beta-lactamase (ESBL) producing
Escherichia coli: importance of international travel. Journal of Infection 2008, 57(6), 441–448.
196. Pitout, J.D.; Campbell, L.; Church, D.L.; Wang, P.W.; Guttman, D.S.; Gregson, D.B. Using a commercial DiversiLab semiautomated repetitive
sequence-based PCR typing technique for identification of Escherichia coli clone ST131 producing CTX-M-15. Journal of Clinical
Microbiology 2009, 47(4), 1212–1215.
197. van der Bij, A.K.; Pitout, J.D. The role of international travel in the worldwide spread of multiresistant Enterobacteriaceae. Journal of Antimicrobial
Chemotherapy 2012, 67(9), 2090–2100.
198. Haigh, J. The accumulation of deleterious genes in a population--Muller's Ratchet. Theor Popul Biol 1978, 14(2), 251-67.
199. Landis, M.J.; Bedford, T. Phylowood: interactive web-based animations of biogeographic and phylogeographic histories. Bioinformatics 2014, 30(1),
123-4.
200. Illingworth, C.J.; Mustonen, V. A method to infer positive selection from marker dynamics in an asexual population. Bioinformatics 2012, 6, 831-7.
201. Skoglund, P.; Sjödin, P.; Skoglund, T.; Lascoux, M.; Jakobsson, M. Investigating Population History Using Temporal Genetic Differentiation. Mol
Biol Evol 2014, doi: 10.1093/molbev/msu192.
202. Foll, M.; Poh, Y.P.; Renzette, N.; Ferrer-Admetlla, A.; Bank, C.; Shim, H.; Malaspinas, A.S.; Ewing, G.; Liu, P.; Wegmann, D.; et al. Influenza virus
drug resistance: a time-sampled population genetics perspective. PLoS Genet 2014, 10(2), e1004185.
203. Luksza, M.; Lässig, M. A predictive fitness model for influenza. Nature 2014, 507(7490), 57-61.
204. Rasmussen, D.A.; Volz, E.M.; Koelle, K. Phylodynamic inference for structured epidemiological models. PLoS Comput Biol 2014, 10(4), e1003570.
205. Török, M.E.; Reuter, S.; Bryant, J.; Köser, C.U.; Stinchcombe, S.V.; Nazareth, B.; Ellington, M.J.; Bentley, S.D.; Smith, G.P.; Parkhill, J.; et al.
Rapid whole-genome sequencing for investigation of a suspected tuberculosis outbreak. J Clin Microbiol 2013, 51(2), 611-4.
206. Harris, S.R.; Cartwright, E.J.; Török, M.E.; Holden, M.T.; Brown, N.M.; Ogilvy-Stuart, A.L.; Ellington, M.J.; Quail, M.A.; Bentley, S.D.; Parkhill, J.;
et al. Whole-genome sequencing for analysis of an outbreak of meticillin-resistant Staphylococcus aureus: a descriptive study. Lancet Infect
Dis 2013, 13(2), 130-6.
207. Gardy, J.L.; Johnston, J.C.; Ho Sui, S.J.; Cook, V.J.; Shah, L.; Brodkin, E.; Rempel, S.; Moore, R.; Zhao, Y.; Holt, R.; et al. Whole-genome
sequencing and social-network analysis of a tuberculosis outbreak. N Engl J Med 2011, 364(8), 730-9.
208. Török, M.E.; Harris, S.R.; Cartwright, E.J.; Raven, K.E.; Brown, N.M.; Allison, M.E.; Greaves, D.; Quail, M.A.; Limmathurotsakul, D.; Holden,
M.T.; et al. Zero tolerance for healthcare-associated MRSA bacteraemia: is it realistic? J Antimicrob Chemother 2014, 69(8), 2238-45.
209. Bull, J.J. Evolution of phenotypic variance. Evolution 41(2), 1987, 303-315.
210. Vander Heiden, M.G.; Cantley, L.C.; Thompson, C.B. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science
2009, 324(5930), 1029-33.
211. Oren, Y.; Smith, M.B.; Johns, N.I.; Kaplan Zeevi, M.; Biran, D.; Ron, E.Z.; Corander, J.; Wang, H.H.; Alm, E.J.; Pupko, T. Transfer of noncoding
DNA drives regulatory rewiring in bacteria. Proc Natl Acad Sci U S A 2014, doi: 10.1073/pnas.1413272111.
212. Munsky, B.; Neuert, G.; van Oudenaarden, A. Using gene expression noise to understand gene regulation. Science 336, 2012, 183-187.
213. Yun, H.S.; Hong, J.; Lim, H.C. Regulation of ribosome synthesis in Escherichia coli: effects of temperature and dilution rate changes. Biotechnol
Bioeng 1996, 52, 615-624.
214. Zaslaver, A.; Kaplan, S.; Bren, A.; Jinich, A.; Mayo, A.; Dekel, E.; Alon, U.; Itzkovitz, S. Invariant distribution of promoter activities in Escherichia
coli. PLoS Comput Biol 2009, 5(10), e1000545.
215. Sabarly, V.; Bouvet, O.; Glodt, J.; Clermont, O.; Skurnik, D.; Diancourt, L.; de Vienne, D.; Denamur, E.; Dillmann, C. The decoupling between
genetic structure and metabolic phenotypes in Escherichia coli leads to continuous phenotypic diversity. J Evol Biol 2011, 24(7), 1559-71.
216. Kiviet, D.J.; Nghe, P.; Walker, N.; Boulineau, S.; Sunderlikova, V.; Tans, S.J. Stochasticity of metabolism and growth at the single-cell level. Nature
2014, doi: 10.1038/nature13582.
217. Rodriguez, M.; Good, T.A.; Wales, M.E.; Hua, J.P.; Wild, J.R. Modeling allosteric regulation of de novo pyrimidine biosynthesis in Escherichia coli.
J Theor Biol 2005, 234, 299-310.
218. Hart, Y.; Madar, D.; Yuan, J.; Bren, A.; Mayo, A.E.; Rabinowitz, J.D.; Alon, U. Robust control of nitrogen assimilation by a bifunctional enzyme in
E. coli. Mol Cell 2011, 41(1), 117-27.
219. Levine, E.; Hwa, T. Stochastic fluctuations in metabolic pathways. Proc Natl Acad Sci USA, 2007, 104, 9224-9229.
220. Wilson, W.A.; Roach, P.J.; Montero, M.; Baroja-Fernández, E.; Muñoz, F.J.; Eydallin, G.; Viale, A.M.; Pozueta-Romero, J. Regulation of glycogen
metabolism in yeast and bacteria. FEMS Microbiol Rev 2010, 34(6), 952-85.
221. El-Mansi, E.M.; Holms, W.H. Control of carbon flux to acetate excretion during growth of Escherichia coli in batch and continuous cultures. J Gen
Microbiol 1989, 135, 2875-2883.
222. Bremer, H.; Dennis, P.P. Modulation of chemical composition and other parameters of the cell at different exponential growth rates. In EcoSal Escherichia coli and Salmonella, cellular and molecular biology. Curtiss III, R.; 2008, ASM Press.
223. Baguley, D.; Lim, E.; Bevan, A.; Pallet, A.; Faust, S.N. Prescribing for children — taste and palatability affect adherence to antibiotics: a review.
Arch Dis Childhood 2012, 97, 293-297.
224. Ambrose, P.G.; Bhavnani, S.M.; Ellis-Grosse, E.J.; Drusano, G.L. Pharmacokinetic-pharmacodynamic considerations in the design of hospitalacquired or ventilator-associated bacterial pneumonia studies: look before you leap! Clin Infect Diseases 2010, 51, S103-S110.
225. Baquero, F.; Negri, M.C. Selective compartments for resistant microorganisms in antibiotic gradients. Bioessays 1997, 19, 731–736.
226. Hermsen, R.; Deris, J.B.; Hwa, T. On the rapidity of antibiotic resistance evolution facilitated by a concentration gradient. Proc Natl Acad Sci U S A
2012, 109(27), 10775-80.

17

227. Gullberg, E.; Cao, S.; Berg, O.G.; Ilbäck, C.; Sandegren, L.; Hughes, D.; Andersson, D.I. Selection of resistant bacteria at very low antibiotic
concentrations. PLoS Pathog 2011, 7, e1002158.
228. Moreno-Gamez, S.; Hill, A.L.; Rosenbloom, D.I.S.; Petrov, D.A.; Nowak, M.A.; Pennings, P. Imperfect drug penetration leads to spatial
monotherapy and rapid evolution of multi-drug resistance. BiorXiv Epub Dec 2014, doi: http://dx.doi.org/10.1101/013003.
229. Greulich, P.; Waclaw, B.; Allen, R.J. Mutational pathway determines whether drug gradients accelerate evolution of drug-resistant cells. Phys Rev
Lett 2012, 109(8), 088101.
230. Levin, B.R.; Concepcion-Acevedo, J.; Udekwu, K. Persistence: a copacetic and parsimonious hypothesis for the existence of non-inherited resistance
to antibiotics. Current Opinion in Microbiology 2014, 21, 18-21.
231. Kussell, E.; Leibler, S. Phenotypic diversity, population growth, and information in fluctuating environments. Science 2005, 309(5743), 2075-8.
232. Deris, J.B.; Kim, M.; Zhang, Z.; Okano, H.; Hermsen, R.; Groisman, A.; Hwa, T. The innate growth bistability and fitness landscapes of antibioticresistant bacteria. Science 2013, 342(6162), 1237435.
233. Moyed, H.S.; Bertrand, K.P. hipA, a newly recognized gene of Escherichia coli K-12 that affects frequency of persistence after inhibition of murein
synthesis. J Bacteriol 1983, 155(2), 768-75.
234. Young, B.C.; Golubchik, T.; Batty, E.M.; Fung, R.; Larner-Svensson, H.; Votintseva, A.A.; Miller, R.R.; Godwin, H.; Knox, K.; Everitt, R.G.; et al.
Evolutionary dynamics of Staphylococcus aureus during progression from carriage to disease. Proc Natl Acad Sci USA 2012, 109, 4550-4555.
235. Lieberman, T.D.; Flett, K.B.; Yelin, I.; Martin, T.R.; McAdam, A.J.; Priebe, G.P.; Kishony, R. Genetic variation of a bacterial pathogen within
individuals with cystic fibrosis provides a record of selective pressures. Nat Genet. 2013, 46(1), 82-7.
236. Chung, J.C.; Becq, J.; Fraser, L.; Schulz-Trieglaff, O.; Bond, N.J.; Foweraker, J.; Bruce, K.D.; Smith, G.P.; Welch, M. Genomic variation among
contemporary Pseudomonas aeruginosa isolates from chronically infected cystic fibrosis patients. J Bacteriol 2012, 194(18), 4857-66.
237. Folkvardsen, D.B.; Svensson, E.; Thomsen, V.Ø.; Rasmussen, E.M.; Bang, D.; Werngren, J.; Hoffner, S.; Hillemann, D.; Rigouts, L. Can molecular
methods detect 1% isoniazid resistance in Mycobacterium tuberculosis? J Clin Microbiol 2013, 51(5), 1596-9.
238. Korolev, K.S.; Müller, M.J.; Karahan, N.; Murray, A.W.; Hallatschek, O.; Nelson, D.R. Selective sweeps in growing microbial colonies. Phys Biol
2012, 9(2), 026008.
239. Coward, C.; Restif, O.; Dybowski, R.; Grant, A.J.; Maskell, D.J.; Mastroeni, P. The effects of vaccination and immunity on bacterial infection
dynamics in vivo. PLoS Pathog 2014, 10(9), e1004359.
240. Webb, G.F.; D’Agata, E.M.; Magal, P.; Ruan, S. A model of antibiotic-resistant bacterial epidemics in hospitals. Proc Natl Acad Sci USA 2005,
102(37), 13343–13348.
241. Ankomah, P.; Levin, B.R. Exploring the collaboration between antibiotics and the immune response in the treatment of acute, self-limiting infections.
Proc Natl Acad Sci U S A 2014, 111(23), 8331-8.
242. Stoesser, N.; Batty, E.M.; Eyre, D.W.; Morgan, M.; Wyllie, D.H.; Del Ojo Elias, C.; Johnson, J.R.; Walker, A.S.; Peto, T.E.; Crook, D.W. Predicting
antimicrobial susceptibilities for Escherichia coli and Klebsiella pneumoniae isolates using whole genomic sequence data. J Antimicrob
Chemother. 2013, 68, 2234-44.
243. Köser, C.U.; Ellington, M.J.; Peacock, S.J. Whole-genome sequencing to control antimicrobial resistance. Trends Genet 2014, 30, 401–407.
244. Raoult, D. Editorial: emerging clones of bacterial epidemics in the genomic area. Clin Microbiol Infect. 2014, 20, 371-2. doi: 10.1111/14690691.12654.
245. Grad, Y.H.; Lipsitch, M. Epidemiologic data and pathogen genome sequences: a powerful synergy for public health. Genome Biology 2014, 15, 538.
246. Taniguchi, Y.; Choi, P.J.; Li, G.W.; Chen, H.; Babu, M.; Hearn, J.; Emili, A.; Xie, X.S. Quantifying E. coli proteome and transcriptome with singlemolecule sensitivity in single cells Science 2010, 329(5991), 533-8.
247. Lalaouna, D.; Eyraud, A.; Chabelskaya, S.; Felden, B.; Massé, E. Regulatory RNAs involved in bacterial antibiotic resistance. PLoS Pathog 2014,
10(8), e1004299.
248. Beaulaurier, J.; Zhu, S.; Sebra, R.; Zhang, X.S.; Rosenbluh, C.; Deikus, G.; Shen, N.; Munera, D.; Waldor, M.K.; Blaser, M.; et al. Single moleculelevel detection and long read-based phasing of epigenetic variations in bacterial methylomes. bioRxiv doi: http://dx.doi.org/10.1101/007823.
249. Fang, G.; Munera, D.; Friedman, D.I.; Mandlik, A.; Chao, M.C.; Banerjee, O.; Feng, Z.; Losic, B.; Mahajan, M.C.; Jabado, O.J.; et al. Genome-wide
mapping of methylated adenine residues in pathogenic Escherichia coli using single-molecule real-time sequencing. Nat Biotechnol 2012,
30(12), 1232-9.

18

